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Summary 
Malignant gliomas remain one of the deadliest of all cancers despite maximal 
therapy. They present unique challenges to therapy with a median survival of 12 months.  
Simultaneous activation of several growth promoting and anti-apoptotic pathways 
represents the basis for the failure of monotherapies against this disease. In order to 
efficiently block growth of glioblastoma (GBM) cells, we have applied several 
combinatorial approaches. We have found that combination of histone deactylase 
inhibitors along with the glycolytic inhibitor 2-deoxyglucose (2DG) efficiently induced 
apoptosis in GBM cells. Furthermore, combination of the microtubule inhibitor 
patupilone and AEE788 –an inhibitor of EGFR, which is frequently activated in gliomas, 
induced apoptosis in GBM cells at doses that as single drugs were not effective. In GBM 
and other cancers, subpopulations of tumor cells with stem cell properties that are 
believed to constitute a tumor cell reservoir, have been identified. GBM cells frequently 
express the progenitor cell markers Nestin and Sox2 and low levels of the differentiation 
markers CNPase, GFAP and !-tubulin III. Bmi1 and Glycogen synthase kinase 3 (GSK3) 
has been implicated in stem cell maintenance, but how Bmi1 regulates differentiation is 
still unknown. We have identified a link between Bmi1 and GSK3 and showed that 
blocking GSK3 may be instrumental to reduce the GBM cancer stem cell pool. We found 
that the GSK3 inhibitors SB216763 as well as Lithium chloride depleted the cancer stem 
cell population in GBM cells and induced tumor cell differentiation, irrespective of the 
CD133 status. Cell proliferation and colony formation were markedly reduced in a dose-
dependent manner.  
Future work giving a deeper insight into the regulatory mechanisms of the 
receptor tyrosine kinases and downstream effectors will help us to identify more specific 
targets. Understanding the mechanisms why some targeted therapies work and others fail 
will finally bring us to the level that efficient long-term treatment strategies can be 
envisaged. 
 3 
 
1. Introduction 
1.1. Cancer  
Cancer is the main cause of death after circulatory diseases in western societies, 
estimated to be the cause of death in one quarter of the population in the EU 
(Niederlaender, 2006). In spite of the advances in the understanding of the molecular 
biology of cancer and of the development of novel therapeutics, cancer remains one of 
the deadliest of all diseases (Maher et al., 2001). Critical factors are to be identified prior 
to the successful introduction of therapeutic interventions.  
Cancer can be viewed as the backside of evolution, which maximizes the 
probability of an organism to survive in a hostile environment (Maynard Smith and 
Szathmáry, 1995). Life originated in an environment with dramatically changing 
conditions, caused in part by exposure to toxic chemical compounds and by continuous 
ultraviolet and gamma-radiation (Maynard Smith and Szathmáry, 1995; Ridley, 1993). In 
order to maintain survival and stability, cells had to repair damage induced by external 
forces, endogenous metabolic toxins and reactive oxygen species, formed during normal 
metabolism. On the other hand, precise cellular repair systems would not allow genetic 
variation of the gene pool and thus, will lead to lack of adaptability (Maynard Smith, 
1989). Perfect organisms with a constant gene pool over their lifetime might extinct when 
exposed to a different environmental parameter. Optimal organisms are formed by a 
trade-off between genetic variability and stability, which includes the risk of acquiring 
mutations that can give rise to cancer (Ridley, 1993). Those mutations may result in 
formation of cells that ultimately break the most basic rules of the organism and exploit 
every possibility of cellular regulatory pathways in order to proliferate indefinitely. The 
huge research effort to understand and combat cancer has tremendously increased the 
general knowledge in cell biology, as most of the cancer genes discovered play an 
important role in pathways regulating DNA repair, cell signaling, cell cycle, programmed 
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cell death and tissue architecture (Alberts, 2002). Normal cells have to receive and 
interpret an elaborate set of signals for the good of the organism, and damaged cells must 
be sacrificed in order to maintain stability of the organism. Only a few cells that can 
evade those protective mechanisms may constitute the candidate cancer initiating cells. 
Those cells may further develop through a microevolutionary process governed by 
several mutations, each conferring a growth advantage progressively leading to a 
selection of ever more aggressive clones (Nowell, 1976). As a result, cancer cells gain the 
ability to reproduce without restraint and colonize foreign tissues leading to death of the 
organism by eventually causing malfunctioning of a vital organ (Knudson, 2001; 
Knudson, 1971; Friend et al., 1986).  
A fundamental feature of most cancer cells is that they are genetically unstable and have 
high mutation rate caused by impaired DNA repair systems and increased replication 
errors paving the way to the microevolutionary selection process. The fact that cancer is a 
multistep process is reflected by the requirements needed by a cell to be capable of 
cancerous growth (Alberts, 2002; Hanahan and Weinberg, 2000): 
 
1. Insensitivity to extrinsic and intrinsic signals regulating cell proliferation 
2. Evasion of apoptosis 
3. Ability to overcome replicative senescense and avoid differentiation inducing signals 
4. Genetic instability 
5. Invasion 
6. Survival in foreign sites. 
 
Genetic alterations needed to push normal cells to a cancerous state can be 
induced in different ways: i) direct environmental factors (e.g. radiation) ii) genetic 
susceptibility to certain environmental factors (e.g. haploinsufficency of a gene involved 
in DNA repair) iii) induction by genetic factors (e.g. presence of an oncogenic mutation 
in the germline). Environmental factors might directly induce genetic alterations that 
target genes involved in the regulation of the cell cycle, survival and genome integrity 
(e.g. induction DNA adducts by cigarette smoking). Main environmental factors leading 
to cancers are cigarette smoking (Witschi et al., 1995), UV-light (Fisher and Kripke, 
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2002) nuclear accidents, nuclear bombs (Little, 2000), and certain chemicals that 
industrial workers are exposed to (e.g. asbestos, benzene, benzidine, vinyl chloride etc.) 
(Jameson, 2000). On the other hand, alterations in genes involved in cancer might already 
be present in germline causing inherited cancer syndromes. Genetic studies of families 
with inherited cancer syndromes have led to the identification of many important genes. 
Among those familial diseases, Li-Fraumeni syndrome (p53), Retinoblastoma (Rb), 
neurofibromatosis (NF1 and NF2), Breast cancer (BRCA1), Colorectal cancer (APC), 
Von-Hippel Lindau syndrome (VHL), Wilms tumor (WT1-4), Xeroderma pigmentosum  
(XP genes), Ataxia-telengiectasia (ATM) and Bloom syndrome (BLM) (Fearon, 1997) 
represent typical examples. Mutations can also occur in somatic cells, causing sporadic 
forms of cancers, which constitutes the majority. Rb (Friend et al., 1986; He et al., 1995), 
p16/p14 (Merlo et al., 1995; Labuhn et al., 2001) p27 (Alleyne et al., 1999) and HDM2 
(Vogelstein and Kinzler, 2004) are examples of those genes that, when mutated, are able 
to equip the cells with a growth advantage and induce the cancerous process. 
1.2. Cancer stem cells 
What are the normal cells of origin of cancer and why is this question so 
important? The cancer-initiating cell could be a normal stem cell, a progenitor cell, or a 
differentiated cell. This question was highly debated in recent years after the discovery of 
cancer stem cells in leukemia (Lapidot et al., 1994) that was followed by the 
identification of cancer stem cells in numerous solid tumors including glioblastoma 
(Ignatova et al., 2002; Lochhead et al., 2001; Singh et al., 2003; Singh et al., 2004; Al-
Hajj et al., 2003; Gibbs et al., 2005; O'Brien et al., 2007; Ricci-Vitiani et al., 2007; Xin et 
al., 2005; Burger et al., 2005). The failure to eradicate cancer may be as fundamental as a 
misidentification of the target. Identification of a defined cell that could function as a 
therapeutic target would facilitate development of successful treatment strategies (Figure 
1). Conventional non-specific cancer treatments such as chemotherapy and radiotherapy, 
which act on all dividing cells, usually fail, and the disease recurs.  
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One of the most typical and interesting features of stem cells is the self-renewal 
characteristic that is also found in the cancer cells. Tumors might arise from the 
transformation of normal stem cells into cancer cells since they share many genetic and 
phenotypic features (Austin and Kimble, 1987; Bhardwaj et al., 2001; Chan et al., 1999; 
Ellisen et al., 1991; Gailani and Bale, 1999; Henrique et al., 1997; Korinek et al., 1998; 
Polakis, 2000; Varnum-Finney et al., 2000; Wechsler-Reya and Scott, 2001; Wechsler-
Reya and Scott, 1999; Zhang and Kalderon, 2001; Zhu and Watt, 1999; Figure 2). Those 
cancer initiating cells are the driving force behind tumor propagation as well as the 
critical mediators of both drug- and radiation resistance (Visvader and Lindeman, 2008) 
and the reason behind the failure of conventional therapies. 
 
Figure 1: Tumors are maintained and driven by a rare population of cancer cells termed – 
cancer stem cells. Conventional therapies may kill tumor cells with limited proliferative 
potential but if the cancer stem cells remain viable they will reform the tumor. On the other 
hand, cancer stem cell specific therapies may lead to cures by extinguishing renewal potential 
of the tumor (Reya et al., 2001). 
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Singh and colleagues were able to identify CD133 (also known as Prominin 1) as 
a surface marker of cancer stem cells in brain tumors. As few as 100 of these CD133-
positive cells found to be able to induce tumors in transplantation experiments and 
yielded phenocopies of the initial neoplasia (Singh et al., 2003; Singh et al., 2004). The 
expression of multi drug resistance proteins (Dean et al., 2005) and efficient DNA repair 
mechanisms (Bao et al., 2006) render CD133-positive cells highly resistant to chemo- 
and radiotherapeutic regimens. However, CD133 may not be a reliable stem cell marker 
for brain tumors as recent studies showed CD133-negative cells that are able to form 
tumors in immunocompromised mice. The other hypothesis consists of the concept that 
an adult astrocyte can dedifferentiate becoming a cancer cell as shown in an animal 
model (Bachoo et al., 2002). If cancer originates from cancer stem cells then any 
successful therapy will have to also eradicate this tumor promoting cell population to 
prevent recurrence. 
Figure 2: Several signaling pathways regulating normal stem cells found to 
be deregulated in cancer (Reya et al., 2001)  
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1.3. General features of brain tumors 
Any brain tumor having the histological, immunohistochemical and ultrastructural 
proof of glial cell differentiation is defined as ”glioma”. Gliomas are classified into 
different groups according to their degree of malignancy. The most widely accepted 
classification sytem is based on World Health Organization (WHO), which classifies glial 
tumors into four basic grades (I-IV astrocytoma) according to the degree of malignancy 
defined by histopathological criteria. Grade I gliomas are usually benign, well 
circumscribed and seldom progress into more advanced stages, whereas grades II to IV 
are malignant and readily infiltrative into the brain parenychma. Survival ranges from 3 
to 10 years in low-grade astrocytoma (grade II) from 2 to 5 years in Grade III anaplastic 
astrocytomas, and about 1 year in grade IV tumors also known as glioblastomas (GBM) 
(Maher et al., 2001). In Switzerland the incidence rate per 100,000 population/year, was 
estimated as 3.32 in males and 2.24 in females (Ohgaki et al., 2004).  
The blood-brain barrier (BBB) is an important cellular structure that prevents 
toxic substances from entering the brain and allows passage of nutrients and small 
compounds. On the other hand, it constitutes a major obstacle to the delivery of 
pharmacological agents into the tumor tissue, an important problem in the treatment of 
brain tumors (Sathornsumetee et al., 2007). The blood-brain barrier is formed by the tight 
junctions made by endothelial cells, other vascular cells and astrocytic foot processes and 
involves several active efflux transport systems including the prototype member P-
glycoprotein (P-gp) (Pardridge, 2003). Drugs that could have been invaluable for the 
treatment of brain tumors either fail to pass the BBB or fail to pass blood-tumor barrier, 
which is limited by the fact that tumors have a high interstitial pressure (Boucher et al., 
1997). 100% of large molecular and 98% of small molecular drugs do not cross the BBB. 
Another approach to overcome BBB is a bur hole-based drug delivery via intracerebral 
catheters (Merlo et al., 1999). Although those methods might efficiently supply drugs 
into the tumor bed, they may not readily target metastatic cells as the diffusion of the 
drugs to other areas of the brain than the tumor could be limited.  A further development 
is direct intra-tumoral injection of small peptides that are distributed in the tumor mass 
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prior to resection (Kneifel et al., 2006). Efficient BBB drug targeting strategies can be 
built with the knowledge of the endogenous transporters within the brain capillary 
endothelium. The development of novel carrier molecules such as conjugating a tumor-
targeting domain to a protein that can bind to molecules expressed on the BBB, and 
mediating their entry into tissue are strongly needed. 
 
1.4. Glioblastoma 
Glioblastoma (GBM) is the most frequent and most aggressive type of primary 
brain tumor in humans, accounting approximately for 50% of all tumors of glial origin 
and 20% of all intracranial tumors (Louis et al., 2007). Any disease with prevalence of 
less then 50 in 100.000 is classified as an orphan disease. Those diseases have not often 
been adopted by the pharmaceutical industry, as the number of patients affected is too 
low to make the drug-development cost-effective. Glioblastoma belongs to this class of 
diseases with an occurence of about 5-10 per 100,000 persons (Rich et al., 2004).  
Malignant gliomas present unique challenges to therapy and remain one of the 
deadliest of all cancers with a median survival of 12 months. Even in the most favorable 
cases patients die within two years (Deorah et al., 2006). The duration of survival 
associated with malignant gliomas has improved only minimally despite tremendous 
efforts of therapy and improvement in the understanding of the molecular biology of 
cancer and in molecular medicine in the last decades (Rich and Bigner, 2004). Unique 
challenges in combating GBM are associated with; i) high vulnerability of the tissue 
where the tumor mass resides ii) diffuse invasiveness of tumor cells into the adjacent 
brain parenchyma iii) recurrence of the disease by rapid growth of the infiltrating cells 
(Merlo, 2003), resulting in very poor prognosis. GBM can manifest as de novo lesion  
(primary GBM, >90%) or progress from less undifferentiated low-grade astrocytoma 
(secondary GBM) (Ohgaki and Kleihues, 2007). Primary GBM usually develops in older 
patients as a highly aggressive and invasive de novo lesion, without any clinical or 
histological evidence of a less malignant precursor lesion. Secondary GBM manifest in 
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younger patients and develop through progression from low-grade to high-grade 
astrocytoma in a time range of 5 to 10 years. Although there are common pathways 
employed, primary and secondary GBMs develop through distinct molecular pathways 
(Collins, 1998; Rasheed et al., 1999). Primary GBM manifests with loss of 
heterozygosity at 10q (70% of cases), EGFR amplification (36%), p16INK4a deletion 
(31%) and PTEN mutations (25%). On the other hand, in secondary GBM etiology TP53 
mutations are the most frequent and earliest detectable genetic alterations, already present 
in 60% of precursor low-grade astrocytomas. Additionally, primary and secondary 
glioblastomas manifests significant differences in their pattern of promoter methylation 
and in expression profiles at RNA and protein levels. (Ohgaki and Kleihues, 2007; Maher 
et al., 2001; Wechsler-Reya and Scott, 2001; Zhu and Parada, 2002; Figure 3). Recently, 
in a cancer genome-sequencing project, the IDH1 gene was identified as a gene, which is 
somatically mutated predominantly in secondary glioblastomas (Parsons et al., 2008). It 
was later found that IDH1 mutations are a strong predictor of better prognosis and a 
highly selective molecular marker to distinguish primary glioblastomas from secondary 
glioblastomas that complements clinical findings (Nobusawa et al., 2009). The IDH1 
gene which encodes isocitrate dehydrogenase (IDH) 1 catalyzes the oxidative 
carboxylation of isocitrate to "-ketoglutarate, resulting in the production of NADPH in 
the Krebs cycle (Devlin, 2006). IDH1 mutations dominantly inhibit the function of the 
enzyme through the production of catalytically inactive heterodimers (Zhao et al., 2009). 
Further studies will provide molecular explanations for the role of IDH1 mutations in 
GBM.  
It is predictable that the mutations occurring in the precursor cancer cell in 
primary GBM creates a much more unstable genetic background that facilitates further 
mutations which accelerates tumor growth by selection of more malignant clones 
(Nowell, 1976). In secondary GBM, specific founder mutations might cause milder 
instability and may require longer time lapse in order to gain further mutations to 
progress to a GBM (Ohgaki and Kleihues, 2007). 
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Standard therapy, including complete surgical resection is not successful because 
of the infiltrative behavior of the tumor cells, which already invade multiple parts of the 
brain during the progression of the disease even long before the time of the diagnosis. 
Surgical intervention is usually followed by aggressive chemo- and radio-therapeutic 
regimens, which has proven limited efficacy because of i) the expression of multi-drug 
resistance proteins (Dean et al., 2005), ii) efficient DNA repair mechanisms of 
glioblastoma cells (Bao et al., 2006), iii) serious side effects induced from the therapy. 
Identifying novel molecular targets, and therapeutical strategies with improved efficacy 
and reduced toxicity, are strongly demanded. 
Figure 3: Genetic pathways to primary and secondary glioblastomas 
(Ohgaki and Kleihues, 2007). 
 12 
1.5. Main pathways affected  
Key cellular pathways, controlling apoptosis, cell cycle arrest, proliferation, 
survival and DNA repair are the most frequently disrupted pathways in GBM due to 
alterations in TP53, p16/p14, RB, PTEN, EGFR and PDGFR genes (Figure 4). 
EGFR/PTEN/PKB pathway  
Epidermal growth receptor (EGFR) is a key protein involved in the development 
of primary GBM (Kita et al., 2007), its overexpression occurs in about 60% of primary 
GBMs but rarely in secondary GBM (ca. 10%) (Dropcho and Soong, 1996). The most 
frequent mutant form is the constitutively active variant 3 (EGFRvIII) with the deletions 
of exons 2 to 7 (Huang et al., 1997). Activation of the EGF receptor in turn promotes cell 
proliferation in part through the suppression of the p27 gene via the PI3K/PKB pathway 
and partly due to the activation of the Ras/MAPK pathway (Narita et al., 2002). PKB 
activation due to the constitutive active EGFR results in increased cell proliferation and 
cell survival. LOH at chromosome 10 is the most frequent genetic alteration in GBM. 
PTEN is located at chromosome 10 and negatively regulates PI3K by 
dephosphosphorylating phosphatidyl inositol triphosphate (PIP3). In PTEN mutant cells, 
PKB is hyperphosphorylated by PI3K (Maehama and Dixon, 2000) and this leads to 
increased proliferation and inhibition of apoptosis. 
TP53/HDM2/p14ARF Pathway 
The most frequent alteration found in diffuse astrocytoma is on the TP53 gene 
(60%). TP53 mutations are also found in primary GBM but at a lower frequency (ca. 
30%) and with a different distribution pattern through the gene. In the cases where p53 is 
not mutated Hdm2 mutations have been detected (Maher et al., 2001) (less than 10% of 
GBM). In addition p14/arf is frequently deleted (76%) in GBM. Disruption of the p53 
pathway leads to evasion of apoptosis and allows proliferation of damaged cells.  
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p16INK4a/RB1 Pathway 
 
A hallmark of astrocytomas is the high mitotic activity, a characteristic shared 
also by primary and secondary GBM. Homozygous deletions of p16 is also frequently 
detected, it is deleted in 31% in primary GBM and 19% secondary GBM. Promoter 
methylation of RB1 gene occur 43% of secondary and in 14% of primary GBM (Ohgaki 
and Kleihues, 2007; Labuhn et al., 2001). RB1 and p16 tumor suppressor proteins control 
the progression through G1 to S phase of the cell cycle. Therefore inactivation of this 
pathway allows G1/S phase progression leading to high mitotic activity. 
Despite many efforts, median survival of GBM patients has not improved more 
than a few months (Rich and Bigner, 2004). Thus, the development of specific bioactive 
molecules that selectively target and inhibit tumor initiation and propagation capacity of 
brain tumor stem cells might allow reduction or elimination of tumor establishment, 
growth and recurrence (Reya et al., 2001). The pursuit of novel agents that fulfill these 
criteria will allow a big leap towards successful treatment of brain tumor patients.  
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Figure 4: Main signaling pathways activated by growth factors. PI3K pathway and the MAP kinase 
pathway are indicated. Designed by Emmanuel Traunecker (mac_manus@hotmail.com)  
1.6. Glycogen synthase kinase 3 pathway 
Glycogen synthase kinase 3 serine/threonine kinase was first identified as an 
enzyme phosphorylating and inactivating glycogen synthase (Doble and Woodgett, 
2003). Far behind its role in glycogen metabolism, further studies showed that GSK3 is a 
key protein in the regulation of numerous signaling pathways. It was shown to be 
inhibited in response to insulin signaling from PKB (Cross et al., 1995). It integrates 
several signaling pathways and regulates many aspects of cell behavior such as cell cycle, 
proliferation, differentiation and apoptosis (Cohen and Goedert, 2004; Doble and 
Woodgett, 2003). Two mammalian GSK3 isoforms are known: GSK3" and GSK3!. 
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Knocking out the GSK3! isoform in mice is embryonically lethal due to massive liver 
degeneration. The presence of the normal " isoform in the GSK3! #$ animals is not 
able to rescue the phenotype (Hoeflich et al., 2000) indicating that at least some of the 
functions of the two isoforms are not redundant. The two isoforms share 97% sequence 
similarity within their kinase domains, but differ significantly outside this region, with 
GSK3" containing an extended N-terminal glycine-rich tail (Frame and Cohen, 2001). 
Controversial findings have been reported regarding the influence of GSK3 on the 
induction of apoptosis. GSK3 has been shown to act as a pro-survival factor in pancreatic 
cancer (Ougolkov et al., 2005) and as a proapoptotic factor in colorectal cancer (Tan et 
al., 2005). These opposite findings indicate that the biological function of GSK3 depends 
upon cellular context and microenvironment. Consequent to its key functions GSK3 is 
involved in the etiology of several diseases such as Alzheimer’s disease (Ryder et al., 
2003), diabetes (Cline et al., 2002), bipolar disorder (Gould and Manji, 2002), and 
recently cancer (Wang et al., 2008b).  
Pathways regulating normal stem cell behavior are also utilized by cancer cells. 
GSK3 is involved in the regulation of Wnt (Miller and Moon, 1996; Yost et al., 1996); 
(Polakis, 2000), Shh (Jia et al., 2002) and Notch pathways (Foltz et al., 2002) which are 
important for embryonic cell fate determination and normal stem cell maintenance. 
Therefore we decided to investigate its role in brain tumor cell identity and maintenance 
of the cancer stem cell pool. 
 
1.7. Bmi1 pathway 
In the recent years it became evident that cancer is not only a disease due to 
genetic mutations but also epigenetic changes play a crucial role influencing malignant 
transition (Jones and Baylin, 2002). Maintenance of chromatin structure is essential for 
appropriate gene expression and every perturbation of the epigenetic regulations can lead 
to inappropriate gene expression and genomic instability, driving normal cells into a 
cancerous state. Polycomb group proteins are epigenetic gene silencers implicated in 
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neoplastic transformation. Bmi1, a member of the polycomb group (PcG) proteins is 
involved in brain development (Leung et al., 2004).  PcG proteins maintain embryonic 
and adult stem cells by forming multiprotein complexes that function as transcriptional 
repressors (Park et al., 2003; Zencak et al., 2005; Liu et al., 2006). Bmi1 was first 
indentified as an oncogene due to its cooperation with Myc in lymphoma formation 
(Jacobs et al., 1999b). It has been shown to block senescence in immortalized mouse 
embryonic fibroblast through the repression of INK4A/Arf (Jacobs et al., 1999a) and it is 
amplified and/or overexpressed in non small cell lung cancer (Vonlanthen et al., 2001), 
colorectal carcinoma (Kim et al., 2006), medulloblastoma (Leung et al., 2004), 
lymphoma (Haupt et al., 1993), multiple myeloma (Matsui et al., 2004) and primary 
neuroblastoma (Nowak et al., 2006). Bmi1 regulates the Ink4a/Arf-locus that is a 
frequent target for homozygous deletions in glioblastoma. Whether Bmi1 is expressed in 
GBM is being debated (Leung et al., 2004) and its role in GBM is not well delineated. In 
a mouse glioma model, Bmi1 had been implicated in brain tumorigenesis in an 
Ink4a/Arf-independent manner (Bruggeman et al., 2007). In addition, it was recently 
shown that inhibition of Bmi1 by micro RNA-128 attenuates glioma cell proliferation and 
self renewal (Godlewski et al., 2008). 
1.8. Combinatorial therapies to overcome therapeutic resistance  
The glucose analog 2-deoxy glucose (2-DG) is a competitive inhibitor of glucose 
uptake and metabolism. Once entering the cells 2-DG is metabolized by the hexokinase 
to 2-deoxy glucose-6-phosphate (2-DG-6-P) which is not a substrate for glucose-6-
phosphate dehydrogenase or phosphohexoisomerase (Wick et al., 1957), therefore cannot 
be further metabolized and accumulate in the cell until dephosphorylation by 
phosphatases. GBM cells are highly proliferative they rely on high sources of energy. A 
cardinal feature of glioblastoma cells is increased glucose uptake aided by high levels of 
hexokinase and glucose transporters. Most glioblastoma cells maintains a huge part of 
their energy supply from the glycolytic pathway as this pathways leads to faster 
production of ATP when compared to oxidative phosphorylation and in order to maintain 
their high growth and proliferation rates. Cancer cells can overcome drug effects by 
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turning on and off different genes to adapt changes in the environment, which requires 
ATP. Thus, blocking cells’ energy production machinery in combination with another 
cytotoxic drug might sensitize the effects of the therapeutics by not giving opportunity to 
turn on and off redundant pathways. Tertiary structure of chromatin is a crucial factor in 
determining whether a particular gene is expressed or not. The accessibility of DNA 
wrapped around nucleosomes determines how efficiently a gene can be transcribed. This 
is regulated in part by a series of chromatin modifying enzymes such as histone 
acetlytransferases (HATs) and histone deactylases (HDAs). The alterations in chromatin 
structure by mutations or aberrant transcription of genes involved in the control of 
histone modifications are key events in cancer initiation. Changes in chromatin structure 
might lead to silencing of tumor suppressor genes and activation of oncogenes leading to 
carcinogenic progression. Various structurally diverse compounds (such as TSA, SAHA, 
trapoxin A, Laq842, sodium butyrate) are available which can bind to histone deactylases 
(HDACs) and induce histone acetylation and consequent reactivation of 2-10% of all 
genes (Mariadason et al., 2000; Egler et al., 2008). 
EGFR, activation is one of the most frequent alterations in primary GBM, 
resulting in simultaneous activation of PKB and RAS pathways (Barker et al., 2001). The 
failure to induce efficient cell death in GBM suggested additional crosstalk between 
downstream pathways. Bioactive compounds such as PKI-166 or AEE788 with EGFR 
protein kinase inhibitory (PKI) activity have been designed and found to have a cytostatic 
effect in vitro on tumor cells that overexpress EGFR (Lane et al., 2001; Traxler et al., 
2004). In addition, the EGFR PKI imatinib (gefitinib) allowed tumor growth control in 
10% of patients with non–small cell lung cancer who carried specific mutations in the 
tyrosine kinase domain (Lynch et al., 2004).  Several small molecular weight compounds, 
of tyrosine kinase inhibitors such as Gleevec or erlotinib/gefinitib, when applied as 
monotherapies, only resulted in limited efficacy in the treatment of GBM (Wen et al., 
2006). Highly mutator phenotype of GBM cells enabled them to gain alterations in 
several growth promoting pathways and there is an obvious cross talk between several 
signaling pathways. In conclusion, these findings supported the hypothesis that in order 
to efficiently induce cell death in GBM cells, combination of two or more drugs is 
required (Failly et al., 2007). 
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2.Results 
Part 1: GSK3! regulates differentiation and growth arrest in 
glioblastoma 
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and Maria Maddalena Lino.  
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Abstract
The oncogenic epidermal growth factor receptor (EGFR)
pathway triggers downstream phosphatidylinositol 3-
kinase (PI3K)/RAS-mediated signaling cascades. In trans-
genic mice, glioblastoma cannot develop on single but only
on simultaneous activation of the EGFR signaling media-
tors RAS and AKT. However, complete blockade of EGFR
activation does not result in apoptosis in human glioblas-
toma cells, suggesting additional cross-talk between
downstream pathways. Based on these observations, we
investigated combination therapies using protein kinase
inhibitors against EGFR, platelet-derived growth factor
receptor, and mammalian target of rapamycin, assessing
glioblastoma cell survival. Clinically relevant doses of
AEE788, Gleevec (imatinib), and RAD001 (everolimus),
alone or in combinations, did not induce glioblastoma cell
apoptosis. In contrast, simultaneous inactivation of the
EGFR downstream targets mitogen-activated protein/
extracellular signal-regulated kinase (ERK) kinase and
PI3K by U0126 and wortmannin triggered rapid tumor
cell death. Blocking EGFR with AEE788 in combination
with sublethal concentrations of the microtubule stabilizer
patupilone also induced apoptosis and reduced cell
proliferation in glioblastoma cells, accompanied by re-
duced AKT and ERK activity. These data underline the
critical role of the PI3K/AKT and the RAS/RAF/mitogen-
activated protein/ERK kinase/ERK signaling cascades in
the cell-intrinsic survival program of sensitive glioblastoma
cell lines. We conclude that drug combinations, which
down-regulate both ERK and protein kinase B/AKT
activity, may prove effective in overcoming cell resistance
in a subgroup of glioblastoma. [Mol Cancer Ther 2007;
6(2):773–81]
Introduction
Glioblastoma multiforme is the most frequent malignant
neoplasm of the human central nervous system. Surgery
can only control the highly proliferative component of the
disease, whereas widespread tumor cell infiltration into
normal brain areas resists radiotherapy and chemotherapy
(1, 2). Amplification and overexpression of the gene
encoding the epidermal growth factor (EGF) receptor
(EGFR) are detected in f50% of glioblastomas and are
mainly associated with disease progression (3, 4). EGFR is a
member of the ErbB family of receptor tyrosine kinases (5).
Small molecular weight compounds with EGFR protein
kinase inhibitory (PKI) activity, such as PKI-166 or AEE788,
have a cytostatic effect in vitro on tumor cells that
overexpress EGFR (6, 7). In addition, treatment of non–
small cell lung cancer with the EGFR PKI imatinib
(gefitinib) resulted in tumor growth control in 10% of
patients (8). In fact, tumors that responded to gefitinib
specifically carried specific mutations in the EGFR tyrosine
kinase domain (8–10). Although responses to gefitinib have
also been observed in a limited number of glioblastoma
cases (11), a specific molecular profile is associated with
response that differs from the lung signature (12–15). To
date, several small molecular weight inhibitors, such as
Gleevec or erlotinib/gefinitib, applied as monotherapies
for the treatment of gliomas, only resulted in limited
effectiveness (16). This has supported the hypothesis that
combination of drugs would be a more appropriate
treatment for glioma.
EGF mediates signaling via phosphatidylinositol 3-kinase
(PI3K)/AKT and RAS/mitogen-activated protein/extracel-
lular signal-regulated kinase (ERK) kinase (MEK)/ERK
pathways (17–19), which are redundantly stimulated by
other activated growth factor receptors (e.g., the insulin-
like growth factor receptor-I; ref. 20). In at least 50% of
glioblastoma, PI3K is activated either by loss of function
of the tumor suppressor PTEN (21) or by gain-of-function
mutations in the PIK3CA gene, which encodes the p110
catalytic subunit of PI3K (22). Interestingly, activated
protein kinase B (PKB)/AKT cooperated with RAS in the
induction of malignant gliomas in a murine brain tumor
model (23). Furthermore, activation of PKB/AKT has been
detected in several types of human cancers and found to
be associated with poor clinical outcome (24–26) and
resistance to chemotherapy and radiotherapy (24, 27, 28).
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Although no RAS mutations have been detected in
glioblastoma, high levels of RAS-GTP have been docu-
mented in high-grade astrocytomas (29, 30). It has been
suggested that ERK plays a critical role in cellular
transformation and resistance to apoptosis (31). Evidence
for a cooperation between AKT and RAS has been proven
by a transgenic mouse model in which both oncogenes are
ectopically expressed in normal astrocytes, giving rise to
glioblastoma, whereas neither AKT nor RAS alone was
sufficient for tumor induction (23).
Several examples of combined therapies have recently
undergone advanced clinical trials in cancer treatment. For
example, lapatinib with tamoxifen has been tested together
in breast cancer (32), and in xenografted tumors (32), PKI
AEE788 has been associated with the rapamycin-derivative
RAD001 for the treatment of glioblastoma (33–35).
Successful drug combinations allow the use of lower
doses, possibly reducing toxicity and limiting the degree
of acquired drug resistance. Given the limited efficacy of
PKI to induce cell death in rapidly proliferating tumor cells,
these inhibitory drugs may depend on the coadministration
of a cytotoxic drug for the induction of cell death rather than
on the coadministration of a second cytostatic compound.
The principle of cytotoxicity of patupilone (epothilone B,
EPO906) relies on the inhibition of microtubule depolymer-
ization, which is lethal for all dividing cells. The antitumor
activity of patupilone has been proven in vitro and in vivo in
lung, breast, colon, and prostate cancers (36). Patupilone
also shows clinical activity in a range of solid tumors (37)
and is now in phase III clinical development.
In the present study, we examined the induction of cell
death on glioblastoma lines in vitro by targeting EGFR/
ErbB2 by the receptor tyrosine kinase inhibitor AEE788
alone or in combination with the cytotoxic compound
patupilone. We further evaluated the activation status of
the EGFR downstream signaling mediators PKB/AKT and
ERK following combined treatment with patupilone
and AEE788. Our study points to a critical role of both
PI3K and ERK in glioblastoma cell survival.
Materials andMethods
Cell Culture
All cell lines were grown at 37jC in a 5% CO2 humidified
atmosphere. DMEM culture medium was supplemented
with 10% FCS and standard antibiotics. Cells were
detached with 1 mL trypsin-EDTA (1!) for 5 min at
37jC. The genetic status of all cell lines at p53, p16, p14ARF ,
and PTEN tumor suppressor genes has been previously
reported (38, 39).
Pharmacologic Inhibitors
AEE788, RAD001, and patupilone (provided by Novartis
Pharma AG, Basel, Switzerland) and U0126 (Promega,
Madison, WI) were dissolved in DMSO as 10 mmol/L
stocks and stored as aliquots at "20jC. Wortmannin
(Sigma, St. Louis, MO) was prepared as a 1 mmol/L stock
solution in DMSO and stored at 4jC, and 12-O-tetradeca-
noylphorbol-13-acetate (TPA; LC Laboratories, Woburn,
MA) was prepared as a 2 mmol/L stock solution in DMSO,
aliquoted, and stored at "20jC. Treatment of the cells with
TPA, U0126, or wortmannin consisted of daily additions
without replacing the medium.
Measurement of Cell Proliferation and Cell Cycle
Profile
In experiments shown in Fig. 1B, cells were grown for
24 h in DMEM supplemented with 10% FCS and for an
additional 24 h in the presence of the drug. Bromodeoxyur-
idine (BrdUrd) was added 1 h before cell harvesting to a
10 Amol/L final concentration. Fluorescence-activated cell
sorting analysis was done according to the manufacturer’s
instructions (Becton Dickinson, Franklin Lakes, NJ). The cell
proliferation assays presented in Figs. 2C and 3B were
done with the Biotrak ELISA System version 2 (Amersham
Biosciences Corp., Piscataway, NJ) according to the manu-
facturer’s instructions. Cells (5 ! 103) were seeded in
96-well plates and grown for 24 h, and drugs were applied
for an additional 24 h. BrdUrd incorporation was allowed
during the last 2 h of treatment. In experiments shown in
Fig. 1D, cells were grown for 24 h in DMEM supplemented
with 10% FCS and for an additional 24 h in the presence of
the drug. Cell DNA content and apoptosis were analyzed on
a FACSCalibur. Cells were trypsinized and fixed in 70% ice-
cold ethanol for 1 h and stained with 50 Ag/mL propidium
iodide for fluorescence-activated cell sorting analysis. The
percentages of cells in the cell cycle phases are reported
(results from three independent experiments).
Measurement of Apoptosis
Expanding cells were subjected to drug treatment for
24 h, briefly washed with PBS, and trypsinized. Cell
suspension was pelleted at 800 rpm for 5 min, fixed in
ice-cold 70% ethanol, and kept at 4jC for 30 min. Cells were
resuspended in a 1! PBS solution containing 50 ng/mL
propidium iodide and 50 Ag/mL RNase. Percentage of cells
in sub-G1 for apoptosis was determined by flow cytometry.
Protein Extraction andWestern Blot Analysis
Cells were washed with PBS, resuspended in 1! SDS
sample buffer (62.5mmol/LTris-HCl, 2%SDS, 10%glycerol,
50 mmol/L DTT), and boiled at 95jC during 5 min; aliquots
were stored at "20jC. Proteins (30 Ag) were separated by
size on SDS-PAGE gels (10%) and transferred to nitrocellu-
lose membranes (Hybond ECL, Amersham Biosciences).
Western blot analysis was done using antibodies against the
following proteins: phosphorylated AKT (Upstate Biotech-
nology, Lake Placid, NY), ERK1/2, phosphorylated ERK,
phosphorylated EGFR (Tyr1173), and EGFR (Santa Cruz
Biotechnology, Santa Cruz, CA) and actin (Sigma). The anti-
AKT antibody was a gift from Dr. Brian Hemmings
(Friedrich Miescher Institute, Basel, Switzerland). Western
blots were developed with enhanced chemiluminescence
reagents (Pierce, Rockford, IL).
Results
SpecificTargeting of the EGF Signaling Pathway by
AEE788
Nearly 50% of primary glioblastomas exhibit amplifica-
tion of the EGFR gene (3, 4), which is also associated with
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poor prognosis. For this reason, the inhibitor of EGFR and
of ErbB receptor protein kinase activities AEE788 has been
considered to be a potent drug to induce cell death in
glioblastoma cell lines. AEE788 was tested for its ability to
induce cell growth arrest and apoptosis in various cell lines
derived from glioblastoma, for which the genetic status of
established cancer genes had been previously defined
(Fig. 1A; refs. 38, 39). For a preliminary determination of
the minimal drug concentration needed to fully prevent
EGFR activation by EGF, increasing concentrations of
AEE788 were applied to the LN229 glioblastoma cell line,
and EGFR/ErbB receptor activation status was monitored
by the presence of EGFR phosphorylated at Tyr1173. To
completely block receptor phosphorylation, 1 Amol/L was
needed (data not shown). Further time course experiment
done with 1 Amol/L AEE788 showed a strong inhibition of
the transient phosphorylation of Tyr1173 as well as of the
degradation of the receptor protein in all seven glioblasto-
ma cell lines tested (Fig. 1B).
Increasing concentrations of AEE788 were applied to
the glioblastoma cell lines, and proliferation was assayed
by integration of BrdUrd after 1 day. At a 1 Amol/L
concentration, AEE788 gives up to 20% of proliferation
reduction compared with the control cell population
(Fig. 1C). Cell cycle analysis after 24 h of 1 and 10 Amol/L
of AEE788 treatment shows an increase of cell population in
the G1 phase (Fig. 1D).
Cell viability was assayed by flow cytometry after 24, 48,
and 96 h. Very low or no apoptosis was induced at drug
concentrations <2 Amol/L as late as 96 h (Fig. 2A). High
levels of apoptosis were observed at unphysiologically
high concentration (10 Amol/L) in five of the seven cell
lines (SF767, LN215, U373, LN229, and LN71). Under the
same condition, LN401 and Hs683 did not show significant
levels of apoptosis. Because AEE788 was not capable of
inducing strong apoptosis in glioblastoma cells when used
as a single drug, we tested whether a specific double or a
triple combination of compounds would significantly
increase the induction rate of apoptosis. For this purpose,
we combined suboptimal doses of AEE788 (0.5 Amol/L)
with two additional biological drugs: Gleevec (imatinib,
0.5 Amol/L) and RAD001 (everolimus, 20 nmol/L). In
gliomas, Gleevec is being explored as a PKI of platelet-
derived growth factor receptor (34), which is activated in
Figure 1. Treatment of glioblasto-
ma cell lines with EGFR inhibitor. A,
genotyping of used glioma cell lines
by Ishii et al. (39). B, cells were
preincubated in the presence or
absence of 1 Amol/L of the EGFR
inhibitor AEE788 during 30 min and
stimulated with 100 ng/mL EGF for
10, 60, and 300 min. EGFR, phos-
phorylated EGFR (Tyr1173), and actin
were detected by Western blot anal-
ysis of cell lysates. C, cells were
incubated during 4 d with increasing
concentrations of AEE788 (0, 1, 2,
5, and 10 Amol/L). Proliferation was
measured by BrdUrd and flow cytom-
etry. Experiments were done in trip-
licate. Points, average of three
independent determinations; bars,
SD. D, cell cycle phase analysis on
glioblastoma cell lines on 1 and 10
Amol/L of AEE788 treatment.
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primary tumors (40, 41). Platelet-derived growth factor
receptor phosphorylation levels correlated with sensitivity
to Gleevec in glioma primary cultures (42). RAD001, a
derivative of rapamycin, inhibits mammalian target of
rapamycin, leading to inactivation of ribosomal S6K1 and
inhibition of cap-dependent translation (43).
The application of the combined drugs to 10 glioblastoma
cell lines for 4 days revealed that there was a combination-
specific and a cell line–specific response with regard to
induction of cell death (Fig. 2B). The cell lines could be
divided into three categories. One group (SF767, LN18, and
LN215; Fig. 2B, left) showed a modest additive induction
of apoptosis by all of the three drugs, reaching a maximum
of 35% of cell death with the triple combination. A second
group of glioblastoma cell lines (LN401, LN71, LN229, and
LN319; Fig. 2B, middle) was basically insensitive to all drug
combinations, showing the same rate of apoptosis as
untreated cells. The third group (Hs683, U373, and U343;
Fig. 2B, right) exhibited a relatively high level of basal
apoptosis (15–20%), which was, however, decreased by the
three drugs applied together. Especially, RAD001 exhibited
an antiapoptotic effect, alone or in combination. No differ-
ences in apoptosis rate were evidenced between PTEN-
mutant (LN215, LN401, LN71, and U373) and wild-type
(Hs683, SF767, and LN229) cell lines on RAD001 applica-
tion. Although, in theory, RAD001 was expected to
overcome the constitutive AKT activation resulting from
loss of PTEN activity.
Taken together, the results indicated that neither single
nor combined application of the three biological drugs, at
physiologic concentration, was able to strongly induce cell
death in glioblastoma cell lines.
Induction of Apoptosis in Glioblastoma Cell Lines by
Patupilone
Because neither the single nor the combined application
of the three biological drugs led to a consistent induction of
apoptosis, we tested whether the combination of AEE788
with a cytotoxic drug could result in a more cooperative
induction of apoptosis. Patupilone is a member of the
group of epothilones, which represent a new class of low
molecular weight compounds that target microtubules by
inhibiting their depolymerization and therefore impairs cell
division (44). Patupilone prevents chromosome alignment
at metaphase and drives cells to undergo apoptosis (45). It
has been shown to exhibit antitumor activity in vitro and
in vivo (36, 37). As a result of inhibition of microtubule
depolymerization, after addition of patupilone, dramatic
changes in cell morphology occurred within 18 h (Fig. 3A,
right). To investigate its ability to induce apoptosis,
glioblastoma cells were treated with increasing concen-
trations of patupilone in the picomolar and nanomolar
concentration range for 4 days (Fig. 3A, left). Although
100% apoptosis was induced in all cell lines when the
highest drug concentration (35 nmol/L) was applied, levels
of apoptosis induced by 0.7 nmol/L patupilone strongly
varied between the cell lines, from Hs683 and LN401, the
most resistant, to LN229, the most sensitive one.
Combined Treatment with AEE788 and Patupilone
Strongly Induced Apoptosis and Reduced Proliferation
of Glioblastoma Cells
AEE788 (1 Amol/L) was applied together with increasing
concentrations of patupilone on cell lines LN71, LN229,
Hs683, and SF767, and cell survival was determined after
4 days (Fig. 3B). The combined drugs induced apoptosis in
Figure 2. Survival of glioblastoma
cell lines on treatment with EGFR
inhibitor and in combination with
Gleevec and RAD001. A, cells were
incubated during 4 d with increasing
concentrations of AEE788 (0, 1, 2,
5, and 10 Amol/L). Apoptosis was
measured by flow cytometry. Experi-
ments were done in triplicate. Col-
umns, average of three independent
determinations; bars, SD. B, combi-
natorial study of biological drugs
AEE788 (A), Gleevec (G), and
RAD001 (R) on glioma cell survival.
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a cooperative manner in LN71 and SF767 but not in Hs683
and LN229 cell lines. In LN71 and SF767 lines, the
patupilone concentration required to induce apoptosis in
50% of cells (AC50) revealed that AEE788 acted as a
sensitizer, reducing the patupilone concentration from a
nanomolar to a picomolar concentration range. Thus,
addition of AEE788 shifted down the amount of patupilone
required to induce apoptosis in 50% of cells, up to 2 orders
of magnitude in SF767 cells. It is noteworthy that the
synergistic effect of patupilone on those glioma cell lines
seemed independent of their respective sensitivities to
AEE788. Consistent with the absence of synergy of
both compounds on LN229 cells, also proliferation was
not affected either by AEE788 or patupilone or by the
combination of both drugs. In contrast, SF767 cells, on
which the AEE788/patupilone synergized the best, had a
significant reduction of proliferation up to 80% (P < 0.001)
after each individual or combined drug application
(Fig. 3C).
Simultaneous Inhibition of Both ERK1/2 and AKT
KinaseActivities Parallels the Induction of Apoptosis
Both signaling pathways, PI3K/AKT and RAS/MEK/
ERK, are under the control of EGF-directed activation of
ErbB receptors. To investigate the activation of these two
pathways, phosphorylation status of the kinases AKT and
ERK was chosen as readouts. AEE788 (1 Amol/L) and
patupilone (0.7 nmol/L), alone and in combination, were
applied for 24 and 72 h to the four glioblastoma cell lines
that differed remarkably in their sensitivities toward those
drugs. In contrast to LN229 and Hs683, LN71 and SF767
Figure 3. Combined treatment of
glioblastoma cells stabilizing micro-
tubules and blocking EGFR. A, in-
creasing concentrations of patupilone
(0.05, 0.1, 0.7, 5, and 35 nmol/L)
were applied to seven cell lines for
4 d and the percentage of viable cells
was determined using flow cytome-
try. Points, average of three indepen-
dent determinations; bars, SD.
Confocal microscopy of LN229 cells
after 18 h of patupilone treatment. B,
cells were treated for 4 d either with
increasing concentrations of patupi-
lone alone or in combination with
1 Amol/L AEE788. Cell survival was
measured by flow cytometry. Points,
average of three independent experi-
ments; bars, SD. C, cells were
treated with 1 Amol/L AEE788 and/
or 0.7 nmol/L patupilone and assayed
for proliferation with BrdUrd by
ELISA. D, top, cells were incubated
during 24 h and 3 d with patupilone
(0.7 nmol/L), AEE788 (1 Amol/L), or
both. Western blot analysis was done
on cell lysates. NT, no treatment;
A, AEE788; P, patupilone. Bottom,
poly(ADP-ribose) polymerase (PARP )
cleavage after 24 h.
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showed full down-regulation of phosphorylation of
both protein kinases after 3 days of combined treatment
(Fig. 3D), accompanied by widespread apoptosis between
85% and 95% of cells. In contrast, LN229 and Hs683 still
retained strong phosphorylation of the two protein kinases
and showed much lower levels of apoptosis. These results
suggested a link between the simultaneous inhibition of the
two EGF-dependent signaling pathways and the induction
of apoptosis triggered by the combination of patupilone
and AEE788. To support this hypothesis, we analyzed the
cleavage status of poly(ADP-ribose) polymerase, which
triggers caspase-dependent apoptosis (46, 47). The cleaved
form of poly(ADP-ribose) polymerase was indeed detected
in glioblastoma cells undergoing apoptosis (Fig. 3E).
Simultaneous Inhibition of AKTand MEK Coopera-
tively Induces Apoptosis in a Subgroup ofGlioblastoma
Cell Lines
To test whether sensitivity of LN71 and SF767 cells to
the AAE788-patupilone combination is due to low phos-
phorylation levels of AKT and/or ERK, inhibitors of PI3K
(wortmannin) and MEK (U0126) were used to abrogate
activation of AKT and ERK pathways. The potential to
induce cell death was tested by applying single or
combined inhibitors to four glioblastoma cell lines and
measuring the proportion of apoptotic cells (Fig. 4A). When
used as a single compound, U0126 was able to induce a
significant level of apoptosis in LN215 and LN229 cells but
to a much lesser extent in U373 and LN401 cells, whereas
wortmannin alone had no or very little effect. However,
strong induction of apoptosis was caused by the combina-
tion of the two inhibitors. On U0126 application, prolifer-
ation was significantly decreased up to 50% in LN229
cell line (P < 0.001), whereas U373 cells showed a 20%
reduction. Again, wortmannin alone had no effect on
reduction of proliferation on both LN229 and U373 cells,
and no synergistic effect was present after drug combina-
tion (Fig. 4B).
U373 and LN401 generally exhibited much less sensitiv-
ity toward the two inhibitors. To examine the long-term
effect of the inhibitors on phosphorylation of AKT and
ERK, the two most sensitive and the two much less
sensitive cell lines were treated for 24 h as well as for
3 days by applying fresh doses of the compounds daily.
The activation status of AKT and ERK was determined
as a readout for drug efficiency (Fig. 4C). In response to
the combination of U0126 and wortmannin, a decrease of
Figure 4. Combined treatment of
glioblastoma cells blocking PI3K and
MEK. A, cell lines were treated with
the MEK inhibitor U0126 (20 Amol/L)
and/or the PI3K inhibitor wortmannin
(1 Amol/L) for 3 d, whereby the
addition of both drugs was repeated
every day. Percentage of apoptotic
cells was measured using flow
cytometry. Columns, mean of three
independent experiments; bars, SD.
B, cells were treated with 20 Amol/L
U0126 and/or 1 Amol/L wortmannin
and assayed for proliferation with
BrdUrd by ELISA. C, Western blot
analysis was done to determine the
relative phosphorylation levels of
ERK1/2 and AKT after 3 d of treat-
ment. U, U0126; W, wortmannin.
D, poly(ADP-ribose) polymerase
(PARP) cleavage after 24 h.
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phosphorylated ERK and phosphorylated AKT occurring
in all glioblastoma lines confirmed the activity of the
two drugs used. Unexpectedly, on treatment with the
MEK inhibitor, U0126, U373, and LN229 cell lines show
a decrease of phosphorylated AKT levels, suggesting a
cross-talk between the RAS/MEK/ERK and PI3K/AKT
pathways.
In the sensitive cell lines LN215 and LN229, simultaneous
inactivation of protein kinases AKT and MEK was
associated with poly(ADP-ribose) polymerase cleavage
and apoptosis (Fig. 4D). However, in the resistant cell lines
U373 and LN401, AKT and MEK inactivation was not
sufficient to trigger apoptosis. There was no correlation
between glioblastoma cell line sensitivity or resistance to
apoptosis and a given genotype (Fig. 1A).
Phorbol Ester TPA Restores Activation of MEK and
Inhibits Induction of Apoptosis
Phorbol ester TPA activates protein kinase C and ERK1/2,
thereby modifying mitogenic signaling pathways (44, 48,
49). When exposed to 20 or 100 nmol/L of TPA, LN215
and LN229 cells showed a strong increase of phosphorylated
ERK levels (Fig. 5A). Treatment of the cell lines with
combined U0126 and wortmannin for 4 days in the presence
of TPA (20 or 100 nmol/L) led to a substantial increase of
activated ERK1/2, whereas phosphorylation was complete-
ly down-regulated without TPA (Fig. 5A). In parallel, the
extent of the induction of apoptosis was determined after
4 days under the same conditions, revealing that the
addition of TPA to both glioblastoma cell lines substantially
decreased the induction of apoptosis caused by the two
inhibitors (Fig. 5B). Taken together, the results further
supported the model of a correlation between down-
regulation of the two signaling pathways and induction of
apoptosis.
Discussion
We report that the combination of the inhibitor of EGFR
kinase AEE788 and of the microtubule depolymerization
inhibitor patupilone synergistically induced death of
glioblastoma cells. Of high interest is that this synergy
occurred at drug concentrations that were not effective to
induce cell death when each drug was applied alone.
AEE788 alone at 1 Amol/L only induced low levels of
apoptosis in glioblastoma cells in vitro . Its main antitumor
activity consists of inhibition of cell growth and motility
(50). Consistently, survival of animals bearing intracranial
tumors had been extended by giving AEE788 at concen-
tration below the maximally tolerated dose (34) and
confirmed a role of AEE788 as an antitumor agent.
However, lasting responses cannot be obtained with a
cytostatic effect but require induction of tumor cell death,
which may only be achieved by drug combinations.
Therefore, we designed a strategy to trigger glioblastoma
cell apoptosis by combining the PKI AEE788 with
patupilone, a compound with strong cytotoxic potential
against various cancer types and also against multidrug
resistance cancer cell lines (51). Glioblastoma cell death
could be triggered in all tumor cell lines in vitro by
35 nmol/L patupilone, a dose that can already be toxic
in vivo . Interestingly, synergistic induction of apoptosis was
observed in glioblastoma cells when using 1 Amol/L
AEE788 in combination with only 0.1 nmol/L patupilone.
Of interest, the genetic backgrounds of the cell lines
that responded the best to the combination therapy with
AEE788 and patupilone were different with regard to the
three main glioma pathways: TP53, PTEN, and p14/p16
(Fig. 1A). Whereas SF767 cells are wild-type at all three loci,
LN71 cells are either mutated or null (39), suggesting that
such a combination could be applied to a wide spectrum of
gliomas. When analyzing the activation status of EGFR,
PKB/AKT, and ERK as readouts for critical pathways in
the glioblastoma signaling network, we found that syner-
gistic induction of apoptosis by combining patupilone and
AEE788 was paralleled by inactivation of PKB/AKT and
ERK. Conversely, the two critical cell signaling mediators
remained active in glioblastoma cells that did not show this
drug synergism. Although AEE788, patupilone, and U0126,
applied individually, reduced glioblastoma cell growth,
AEE788/patupilone and U0126/wortmannin combinations
Figure 5. Phorbol ester TPA antagonizes induction of
apoptosis and maintains AKT and ERK1/2 activities. A,
cells were treated with 20 and 100 nmol/L of TPA in the
presence or absence of wortmannin (W) and U0126 (U)
for 3 d, whereby the additions were renewed every day.
Cell extracts were prepared by the addition of SDS
sample buffer, and Western blot analysis was done.
U0126, 20 Amol/L; wortmannin, 1 Amol/L; TPA, 20 or
100 nmol/L. B, cells were treated in the same way for
4 d and the percentage of dead cells was determined by
flow cytometry.
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did not affect cell growth in a synergistic manner,
suggesting that these processes are driven by distinct
pathways. The importance of the two signaling pathways
PI3K/PKB and RAS/RAF/MEK/ERK for glioblastoma
signaling is further supported by the finding that PI3K is
activated in the majority of human glioblastoma either by
loss of PTEN function (38, 39) or by activating mutations of
PI3KCA (22), whereas growth factor stimulation causes
activation of RAS in glioblastoma (52). Further evidence
stems from a murine transgenic glioblastoma model, in
which simultaneous activation of RAS and PKB gives rise
to malignant gliomas (53, 54). Glioma animal models have
further shown that the combination of ectopic expression of
activated RAS and AKT in the glial lineage (23) led to
spontaneous induction of murine gliomas, whereas an
activated allele of either RAS or AKT alone failed to induce
tumor formation. In analogy to this animal model and the
effects on signaling induced by the described synergism,
we hypothesized that direct inhibition of signaling medi-
ators downstream of EGFR within the PI3K/PKB and
RAS/RAF/MEK/ERK pathways will overcome glioblasto-
ma cell resistance. Therefore, we specifically blocked
activity of both MEK and PI3K, which induced strong
apoptosis in a subgroup of glioblastoma cell lines,
indicating a critical role of these two pathways in
glioblastoma signaling. Combining the MEK inhibitor
U0126 and the PI3K inhibitor wortmannin led to synergistic
induction of apoptosis in LN215 and LN229 cell lines.
Interestingly, although phosphorylation of ERK1/2 and
PKB/AKT was decreased in all cell lines, it was not
associated with apoptosis in resistant lines, suggesting
additional defects in the proapoptotic machinery. Activa-
tion of protein kinase C and ERK1/2 by TPA counteracted
U0126- and wortmannin-dependent apoptosis, confirming
the specificity of drug effect.
An unresolved question is at which cellular level the
intervention has to take place. Our data argue that
combined blocking of signaling mediators downstream of
growth factor receptors, interfering with the signaling
cross-talk, may be more effective than inhibition of a single
cell surface receptor (e.g., EGFR; ref. 13). This view is
supported by other findings in glioblastoma cell lines,
where inhibition of PKB/AKT could be counteracted by a
stimulation of insulin-like growth factor receptor-I, result-
ing in sustained activation of PI3K (19, 20).
In conclusion, our results indicate that the induction of
apoptosis in glioblastoma cell lines requires drug combi-
nation, which down-regulate distinct pathways. Blocking
EGFR activation alone did not induce apoptosis unless
complemented with the microtubule stabilizer patupilone.
If PKIs were targeted without the help of cytotoxic drugs,
combined inhibition of MEK and PI3K was found to be
the most efficient combination to induce glioblastoma cell
death. Drug effects were independent of mutation statuses
at the major glioblastoma pathways (Fig. 1A). Additional
studies are needed to develop other target for treatment of
resistant glioblastoma cells to directly down-regulate key
members of the critical pathways.
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Histone Deacetylase Inhibition and Blockade of the Glycolytic
Pathway Synergistically Induce Glioblastoma Cell Death
Vivian Egler, Serdar Korur, Mike Failly, Jean-Louis Boulay, Roland Imber,
Maria M. Lino, and AdrianMerlo
Abstract Purpose: High-grade gliomas are difficult to treat due to their location behind the blood-brain
barrier and to inherent radioresistance and chemoresistance.
Experimental Design: Because tumorigenesis is considered a multistep process of accumu-
latingmutations affecting distinct signaling pathways, combinations of compounds, which inhibit
nonoverlapping pathways, are being explored to improve treatment of gliomas. Histone deacety-
lase inhibitors (HDI) have proven antitumor activity by blocking cell proliferation, promoting dif-
ferentiation, and inducing tumor cell apoptosis.
Results: In this report, we show that the HDIs trichostatin A, sodium butyrate, and low nano-
molar doses of LAQ824 combinedwith the glycolysis inhibitor 2-deoxy-D-glucose induce strong
apoptosis in cancer cell lines of brain, breast, and cervix in a p53-independent manner. HDIs up-
regulate p21, which is blocked by concomitant administration of 2-deoxy-D-glucose.
Conclusions:We propose simultaneous blockade of histone deacetylation and glycolysis as a
novel therapeutic strategy for several major cancers.
Glioblastoma multiforme (GBM) are the most frequent
human brain tumors. These aggressive, highly invasive, and
neurologically destructive tumors are among the deadliest of
human cancers, with a median survival ranging from 9 to 12
months (1). Despite treatment efforts including new techno-
logical advances in neurosurgery, radiation therapy, and clinical
trials with novel therapeutic agents (2), median survival has not
changed significantly over the past two decades. Meanwhile,
cancer drug development has been moving from conventional
cytotoxic chemotherapeutics to more sophisticated drugs
exploiting biological mechanism of tumorigenesis (3).
In high-grade gliomas, several genes and pathways are altered
due to a severe mutator phenotype that leads to the
accumulation of mutations in critical regulatory genes. Muta-
tions of PTEN, RB, p16/p14, p53 (4), and receptor tyrosine
kinase (5–7) result in up-regulation of pathways that promote
tumor growth, invasion, and resistance to apoptotic stimuli (8).
Besides classic mutations, epigenetic silencing of tumor
suppressor genes frequently leads to dysregulation of signaling
pathways promoting tumorigenesis. Histone acetyltransferase
and histone deacetylase (HDAC) catalyze the acetylation and
deacetylation of lysine residues in the tails of histone proteins
(e.g., lysine residue in histones 3 and 4), regulating the affinity
of the protein transcriptional complexes to the DNA (9). Thus,
the recruitment of histone acetyltransferase and HDAC is
considered as a key element in the dynamic regulation of genes
involved in cellular proliferation and differentiation during
normal development and carcinogenesis (10). HDAC inhib-
itors (HDI) induce re-expression of silenced tumor suppressor
genes (11, 12). HDIs induce differentiation and promote
apoptosis in transformed and cancerous but not in normal cells
(11, 13). HDIs have been classified in different classes: short-
chain fatty acid (as sodium butirrate, valproic acid, etc.),
Epoxides (as depudecin and trapoxin), cyclic peptides, Benza-
mides, and Hydroxamic acids [as trichostatin A (TSA), SAHA,
and LAQ824]. Besides the chemical TSA, sodium butyrate
(NaB), and SAHA (Vorinostat; Food and Drug Administration
approved in 2006), a new potent cinnamic hydroxamic acid
derivate, LAQ824 (13), is currently used in clinical trials for
the treatment of leukemia (14–16). Because this drug passes
the blood-brain barrier, it may potentially be useful for the
treatment of malignant gliomas. In vitro treatment of tumor cell
lines with the LAQ824 caused hyperacetylation of histones,
restoring the expression of <2% of human genes, including the
cell cycle kinase inhibitor p21WAF1/Cip1 (17). High concen-
trations of LAQ824 induce accumulation in G2 phase of the cell
cycle and are selectively toxic for transformed and cancer cells,
whereas lower concentrations induce cell cycle arrest in G1,
increase p21 expression, and only weakly induce apoptosis
(18). The presence or the absence of p21 seems to play a critical
role for the commitment of the targeted cell to either undergo
growth arrest or apoptosis in response to LAQ824.
Maintenance of growth and proliferation of tumor cells
requires high cellular energy levels. Tumor cells have abnormal
mitochondrial functions and essentially rely on glycolysis to
provide ATP for their metabolic requirements even under
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aerobic condition (Warburg effect). As a consequence, tumor
cells have relatively low oxygen needs and can survive in a
hypoxic environment that is not suitable for normal cells.
Human malignant gliomas were shown by 18 F-fluoro-2-
deoxyglucose positron emission tomography studies to be
much more avid of glucose than the normal cortex (19). This
high energy demand of cancer cells is the rational basis to block
glycolysis in cancer cells (20). Glucose metabolism and ATP
production are inhibited by the glucose analogue 2-deoxy-D-
glucose (2-DG). Upon phosphorylation by hexokinase, 2-DG
selectively accumulates in cancer cells by increased glucose
transporter expression, high hexokinase activity, and low
phosphorylase activity (21, 22). 2-DG strongly reduced growth
of tumor cells, when used as single agent (23). Moreover, 2-DG
impairs repair of radiation-induced DNA damage in tumor cells
and promotes tumor cell apoptosis by lowering intracellular
energy levels (24). In the treatment of human GBM, 2-DG
is used as a radiosensitizer in combination with radiotherapy
(24, 25). Moreover, at least two clinical trials using 2-DG for
solid tumor and intracranial metastases are ongoing.
Because HDIs induce re-expression of tumor suppressor genes
in several distinct pathways and cancer cells critically depend
upon continuous energy supply, we explored the therapeutic
potential of a combination of two compounds that simulta-
neously target the epigenetic status and the energy demand of
cancer cells. Synergistic effects may even allow to reduce the drug
Fig. 1. Synergistic induction of apoptosis by 2-DG and HDAC inhibitor LAQ824 in glioma cell lines. Glioma cell lines Hs683, LN401, SF767, U343 and U373 (A), nontumor
lines HEK and rat aorta smooth muscle cell, and normal rat astrocytes (B) were precultured for 48 h in standard medium and were exposed to various concentrations of
LAQ824 in the presence of 2-DG for 72 h. Apoptosis was determined by FACS analysis.The CI calculated for the combination of 25 mmol/L 2-DG and 60 nmol/L LAQ824
were 0.085 (Hs683), 0.066 (LN401), 0.018 (SF767), 0.053 (U343), and 0.005 (U373), respectively. CIs lower than1indicate synergy in all cases (see the Materials and
Methods section for cutoffs).
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dosage of potentially toxic HDIs (26). We found that the
combination of 2-DG andHDIs lead to a strong synergistic effect
resulting in widespread apoptosis of tumor cells of the brain,
breast, and cervix, while sparing normal rat astrocytes.
Materials andMethods
Cell lines and reagents. Hs683, LN401, SF767, U373, U343 glioma
cell lines, for which the genetic status of established cancer genes
TP53, p16/p14 , and PTEN has been defined (4), were cultured in Eagle
medium supplemented with 25 mmol/L glucose, glutamine, standard
antibiotics, and 10% FCS. HCT116, HeLa, MCF-7, HBL, and SKBR-3
cells were cultured in RPMI containing 25 mmol/L glucose, glutamine,
standard antibiotics, and 5% FCS. Parental p21+/+ and engineered p21-/-
HCT116 (27) were a generous gift from Prof. Bert Vogelstein (Johns
Hopkins University, BaltimoreMD). Fresh rat astrocytes were cultured as
described (28). All cells were maintained at 37jC in 5% CO2. All cell
lines were seeded in 3-cm plates at 35% density and grown for 48
h before treatment with the indicated drugs. LAQ824, RAD001, and
Imatinib (Gleevec) were kindly provided by Novartis-Pharma AG. 2-DG,
TSA, and NaB were purchased from Sigma (Saint-Louis). Drug
concentrations described are indicated in the figures.
Western analysis and antibodies. Cells were washed with 1! PBS;
lysed in a buffer containing 2% SDS, 50 mmol/L Tris (pH 6.8), and
0.1 mol/L DTT; boiled; and either used immediately or frozen at -20jC.
Protein lysates were resolved on denaturing SDS-polyacrylamide gels
ranging from 8% to 13% and transferred to nitrocellulose membranes
(Hybond; enhanced chemiluminescence; Amersham Biosciences).
Membranes were probed with the following primary antibodies: anti-
Akt (kindly provided by Dr. Brian Hemmings, Friedrich Miescher
Institute Basel, CH); anti-S6 (kindly provided by Dr. George Thomas,
Friedrich Miescher Institute Basel, CH); antibodies against phosphor-
ylated S6 protein (Ser-240/244), S6K and phospho-S6K (Ser-389),
phospho-Akt (Ser-473), and poly(ADP)ribose polymerase (PARP) were
purchased from Cell Signaling; and antibodies against p21, Cyclin A,
extracellular signal-regulated kinase (p42 and p44), and Phospho–
extracellular signal-regulated kinase (Tyr-204 of p42 and p44) were
purchased from Santa Cruz Biotechnology. Decorated proteins were
revealed using horseradish peroxidase–conjugated anti-mouse or anti-
rabbit immunoglobulins (New England Biolabs) and visualized by
enhanced chemoluminescence (Amersham Biosciences).
Cell viability assay. Cell DNA content and apoptosis were analyzed
with a Flow cytometer (FACS Calibur; BD Biosciences), and statistics
were determined with Cell Quest software. Cells were trypsinized and
fixed in ice-cold 70% ethanol for 1 h, stained with 50 Ag/mL propidium
iodide for fluorescence-activated cell sorting (FACS) analysis. The
percentage of dead cells was determined by the proportion of cells in
pro-G1 phase. Percentages reported result from three independent
experiments.
Combinatorial index calculation. Apoptosis resulted from the
combination of two drugs was analyzed for each cell line using
Fig. 2. Synergistic induction of apoptosis of 2-DG and
HDAC inhibitor LAQ824 in nonglioma cell lines. HeLa
(cervix) and HBL, MCF-7, and SKBR-3 (breast) cancer
cell lines were precultured for 48 h in standard medium
andwere exposed to drugs at various concentrations for
72 h. Apoptosis was determined by FACS analysis.The
CI calculated for the combination of 25 mmol/L 2-DG
and 60 nmol/L LAQ824 were 0.05 (HeLa), 0.4 (HBL),
0.1 (MCF-7), and 0.6 (SKBR-3), respectively, indicating
synergy in all cases.
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CalcuSyn Software (Biosoft) to generate a combination index (CI). A
CI greater than one indicates antagonism. A CI of one indicates an
additive effect. A CI less than one indicates synergism. Specifically, a
value between 0.85 and 0.90 indicate slight synergism, between 0.70
and 0.85 indicates a moderate synergism, between 0.30 and 0.70
indicates synergism, between 0.10 and 0.30 indicates strong synergism,
and <0.1 indicates a very strong synergism.
Cell proliferation assay. Cells (5 ! 103) were seeded in 96-well
dishes and grown for 8 h before treatment. Cells were then exposed to
60 nmol/L LAQ824 and 25 mmol/L 2-DG for 24 h. Bromodeoxy-
uridine incorporation was allowed for the last 2 h. Cell proliferation
Biotrak Elisa system (Amersham Biosciences) was done according to
manufacturer’s instructions. Experiments were done in triplicate. Data
were analyzed with GraphPad prism4 software (GraphPad Software
Corporation).
ATP measurement. Cells cultured in 6-well dishes were treated with
25 mmol/L 2-DG and 60 nmol/L LAQ824, lysed, and incubated at
room temperature for 5 min. ATP levels were measured using a
luciferase-based assay kit (ATP Bioluminescence Assay kit CLS II;
Roche). For each well, ATP levels were normalized by comparison with
the amount of total protein by the Bio-Rad protein assay reagent. All
ATP level measurements and protein assays were done in triplicate.
Results
Blocking glycolysis strongly enhances apoptosis induced by
HDAC inhibition. In malignant glioma cells, we targeted the
histone acetylation pathway with the HDI LAQ824, a known
inducer of cell death in tumor and immortalized cell lines, and
blocked the energy pathway with the glucose analogue 2-DG.
Increasing amounts of LAQ824 and 25 mmol/L 2-DG were
applied to 5 glioma cell lines during 72 hours of treatment, and
apoptosis was monitored by FACS analysis (Fig. 1A). The use of
Fig. 3. HDITSA andNaB combinedwith 2-DG synergistically induce apoptosis.A andB, combinationof 25mmol/L 2-DGwith 0.1to10mmol/LNaB (A) or10 to100 nmol/L
TSA (B) on Hs683 and HeLa cells.C, time course of apoptosis. Hs683 cells precultured for 48 h in standard mediumwere treated with 25 mmol/L 2-DG and 60 nmol/L
LAQ824 for various times. Apoptosis was determined by FACS analysis.D, time course of PARP cleavage. Hs683 were treated as described in 2C. PARP cleavage was
assessed by immunoblotting with an anti-PARP antibody that recognizes the native (116 kDa) and the cleaved forms (86 kDa).
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LAQ824 alone induced relative low levels of apoptosis in a
concentration-dependent manner in all glioma cell lines tested,
whereas 2-DG alone triggered cell death just above baseline.
However, the combination of LAQ824 and 2-DG significantly
enhanced cell death in all lines tested. The extent of synergism
was dependent on the concentration of both drugs but
predominantly on the concentration of 2-DG. The observed
synergism was found to be independent of the p53 status
because p53–wild-type SF767 and U343 and p53-mutant
Hs683, LN401, U373 tumor cells (4) responded in a similar
way (Fig. 1A). The noncancer cell lines HEK293, rat aorta
smooth muscle cells, and rat astrocytes do not show an
enhanced cell death upon combining 2-DG with LAQ824
(Fig. 1B).
To test whether this synergism is also observed in other
tumor types, we tested the 2-DG/LAQ824 combination in
breast and cervix cancer cells MCF-7, HBL, SKBR-3, and HeLa.
We found that these epithelial cancer cells exposed to 2-DG
together with increasing doses of LAQ824 exhibited the same
synergistic induction of cell death as we had consistently
observed in a panel of glioma cells (Fig. 2).
To establish whether the synergistic induction of apoptosis
triggered by the association of LAQ824 and 2-DG represents a
general mechanisms not limited to the drug LAQ824, we used
other HDIs such as TSA, used as a antifungal antibiotic, and the
chemical compound NaB, currently used in clinical trials, in
combination with 2-DG. Consistent with the results obtained
with LAQ824, the association of 2-DG with TSA or NaB
strongly induced apoptosis in glioma and cervical cancer lines
(Fig. 3A and B).
Titration curves established that concentrations of 25 mmol/L
2-DG and 60 nmol/L LAQ824 on Hs683 cells were optimal for
synergy (Fig. 1A). Using these conditions, apoptosis started as
early as 16 hours after treatment and constantly increased until
72 hours, although application of each drug alone induced
little or no cell death at these concentrations (Fig. 3C). The
appearance of the cleaved 86 kDa form of PARP at 16 hours
indicated the onset of apoptosis induction resulting from the
combined treatment. Only low levels of cleaved PARP appeared
after 36 hours of 25 mmol/L 2-DG treatment alone, and no
evidence for cleavage was present upon LAQ824 application
alone (Fig. 3D).
2-DG and LAQ824 affect cell cycle regulation. Next we
studied the effect of LAQ824 on Hs683 and HeLa cell cycle as
single agent or combined with 2-DG. After 24 hours of
treatment, both 2-DG and LAQ824 reduced Hs683 and HeLa
proliferation rate (Fig. 4A). We also analyzed the effect of 2-DG
and LAQ824 on G1 and G2 phases of cell cycle. 2-DG and
LAQ824 as single agents induced G1 and G2 accumulation,
respectively, whereas the combination had minimal effect of G1
and G2 distribution but strongly inhibited the S phase of the
cell cycle (Fig. 4B).
ATP levels and S6 phosphorylation are affected by 2-DG.
Decreased ATP levels lead to the activation of the energy
sensoring kinase AMP-protein kinase. Its activation blocks the
high energy consuming mechanisms by reducing the activation
of S6K and phosphorylation of the ribosomal protein S6 at
serine residues 240 and 244, thereby blocking global protein
translation. To establish whether synergistic induction of
apoptosis by 2-DG and/or LAQ824 involves the energy
Fig. 4. Combination of 2-DG and LAQ824 impairs tumor cell proliferation. Cellular responses to 2-DG/LAQ824 combined treatment for 24 h.A, Hs683 and HeLa cell
proliferation.B, Hs683 cell cycle. C, ATP levels in Hs683 cells. ATP level of untreated cells at time t = 0 was set to100%.D, S6 phosphorylation in Hs683 cells.
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regulatory pathway, ATP levels and the S6 protein phospho-
rylation status were studied. Upon application of 25 mmol/L
2-DG, a dramatic decrease in ATP levels was measured while
the presence of LAQ824 did not alter ATP levels (Fig. 4C). A
comparable decrease was observed by combining both drugs
(Fig. 4C). We observed a decrease in intracellular phosphory-
lated S6 protein in cells treated with 2-DG, whereas the
application of LAQ824 did not alter the phosphorylation of S6
protein (Fig. 4D). Reduction of phosphorylated S6 protein
levels were also observed in HeLa cells line after 2-DG
treatment (data not shown). These results show that 2-DG
dramatically inhibits the energy regulatory pathway and may
considerably block translation by reducing the amounts of
phosphorylated S6 protein.
2-DG abrogates p21 expression induced by LAQ824. We then
investigated the role of p21 in the synergistic induction of
apoptosis by following levels of p21 protein in the glioma cell
line Hs683 after addition of the HDI LAQ824. Starting 4 hours
after LAQ824 treatment, p21 levels showed a transient
prominent increase dropping again to undetectable protein
levels at 48 hours (Fig. 5A). When 2-DG and LAQ824 were
applied together, the p21 increase disappeared (Fig. 5B). To test
whether lowering 2-DG concentrations would reduce p21
protein levels, intermediate doses of 2-DG were combined
with 60 nmol/L of LAQ824. After 8 hours of treatment, p21
levels were significantly augmented in presence of LAQ824 and
reduced with increasing doses of 2-DG (Fig. 5B). Consistent
increase of p21 levels upon addition of LAQ824 alone and its
disappearance after 2-DG treatment was observed in HeLa cells
(Fig. 5B) and all other glioma cell lines tested (data not shown).
Moreover, as with LAQ824, the HDIs TSA and NaB caused an
increase in p21 protein levels that was strongly reduced in the
presence of 2-DG both on the glioma line Hs683 and the cervix
cancer line HeLa (Fig. 5C).
Lack of p21 protein sensitizes cancer cells to apoptosis. To test
whether the 2-DG effect on p21 protein is a critical factor in the
synergistic induction of apoptosis, we tested the effect of the
HDI LAQ824 on the parental colon cancer cell line HCT116,
which is wild-type for p21 (p21+/+), and its p21-/- derivate (27).
HCT116 p21+/+ cells were very sensitive to LAQ824, undergoing
rapid apoptosis. Nevertheless, HCT116 p21-/- cell line showed a
15% to 20% increase of apoptosis compared with the wild-type
constellation HCT116 p21+/+, both after 24 hours and after
72 hours of application of the HDI LAQ824 (Fig. 6A). Combi-
nation of LAQ824 and 2-DG on HCT116 p21+/+ and p21-/- cells
did not change the different apoptosis rates observed (Fig. 6B).
These data show that the reduction of p21 protein levels may
increase apoptosis rate upon treatment with the HDI LAQ824.
Synergistic induction of apoptosis in fresh ex vivo GBM cell
cultures after the combined treatment of 2-DG with LAQ824.
Because commonly used cell lines undergo many cycle
divisions with a high probability to increase their genetic
mutator phenotype, we tested LAQ824 and 2-DG in combina-
tion on an ex vivo GBM-derived cell line BS153. BS153 cell line
showed a synergistic response upon LAQ824/2-DG combina-
tion when compared with the single drug application (Fig. 6C).
Thus, targeting the energy and the epigenetic pathways may be
an efficient treatment also in ex vivo GBM cell lines.
LAQ824 specifically synergizes with 2-DG but not with the
rapamycin derivative RAD001 or Imatinib. We tested the
specificity of the synergy between LAQ824 and 2-DG by
measuring apoptosis of glioma cells Hs683, U87, and U373 in
response to LAQ824 in combination with other compounds
that target alternative nonoverlapping glioma pathways such as
the mammalian target of rapamycin inhibitor RAD001 or the
platelet-derived growth factor inhibitor Imatinib. Neither
combination increased the apoptosis rate in GBM cell lines
(Fig. 6D), showing the specificity of synergy between combined
Fig. 5. p21levels are increased in the
course of the synergistic induction of
apoptosis. A, time course of Hs683 p21
levels in response to 60 nmol/L LAQ824
(A). B and C, p21status of Hs683 and
HeLa cells after 8 h of 2-DG/LAQ824
(B) and 2-DG/TSA or 2-DG/NaB
(C) combined treatment.
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inhibition of histone deacetylation and of the glycolytic path-
way in glioma cells.
Discussion
Combination of drugs that inhibit nonoverlapping cancer
pathways is a rational strategy to control tumor growth. A
synergistic effect after the use of two drugs can lower the
single dosage and increase the patient tolerance, reducing
collateral effects. We have shown that 2-DG, an inhibitor of
the glycolytic pathway, sensitizes glioma cells treated with
HDI to undergo apoptosis. Epigenetic silencing of tumor
suppressor genes leads to dysregulation of cellular processes
promoting tumorigenesis. It is well-established that 2-DG and
HDIs such as Vorinostat (butyrates) are able to pass the
blood-brain barrier, a prerequisite for glioma treatment, and
are also well-tolerated by patients. We found that HDIs such
as TSA or NaB strongly synergize with 2-DG in the induction
of tumor cell death. We then tested LAQ824, an HDI that is
currently in clinical trial against leukemia and displays good
blood-brain barrier penetration, for its potential as a cancer
drug against malignant glioma. In response to higher nano-
molar doses of LAQ824, glioma cell lines underwent
apoptosis, whereas lower nanomolar doses only had a
cytostatic effect with markedly reduced cell death. However,
a combination of 2-DG and low nanomolar concentrations of
LAQ824 showed a marked synergism in the induction of
tumor cell apoptosis, not only in GBM cells, but also in breast
and cervix cancer cells, regardless of their p53 status. The
observed synergism seems to be specific because combination
with other drugs that target glioma pathways such as RAD001
and Imatinib did not lead to any increased apoptosis rate
when combined with LAQ824.
The glycolysis demand of many tumors represents the
rationale to block glucose metabolism in addition to histone
deacetylation inhibition. We first tested the effect of 2-DG per
se on human GBM cell line survival, which induced apoptosis
in GBM cells only at high concentrations (25 mmol/L) but
Fig. 6. HCT116 p21-/- cells show increased apoptosis rate upon LAQ824 treatment.A, apoptotic responses of p21-/- and p21+/+ HCT116 colon cancer cells treated with
60 nmol/L LAQ824 for 24 or 72 h. B, apoptotic responses of p21-/- and p21+/+ HCT116 cells treated with 60 nmol/L LAQ824 alone or in combination with 25 mmol/L
2-DG for 72 h. Apoptosis was determined by FACS analysis.C, apoptotic responses of fresh ex vivo derived glioblastoma cell line BS153 to 60 nmol/L LAQ824 and/or
25 mmol/L 2-DG treatment for 72 h.D, RAD001or Imatinib do not synergize with LAQ824 to induce apoptosis in glioma cell lines. Apoptotic responses of glioma lines
Hs683, U87, and U373 in the presence of 60 nmol/L LAQ824 combined with either 20 Amol/LRAD001or10 mmol/L Imatinib.
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efficiently inhibits proliferation of all glioma cell lines.
Glycosylation of essential proteins such as transcription factors
can be profoundly affected by the absence of glucose (29) or by
blocking glycolysis with 2-DG (30). Under conditions of energy
starvation, the decreased ATP to AMP ratio activates the first
cellular energy sensor, the tumor suppressor LKB1 (31), and the
Tuberous Sclerosis Complex TSC1/2 (32) activate 5¶AMP-
protein kinase. Activation of AMP-protein kinase leads to a
reduction of global translation and cell size by inhibiting
phosphorylation of the downstream effectors such as the
mammalian target of rapamycin (33), the S6 40S ribosomal
kinase protein kinase, and the eukaryotic initiation factor 4E
binding protein. 2-DG attenuates the transcription factor
activity of Sp1 by influencing its O-GlcNAcylation levels (30).
Because many transcription factors are modified by O-GlcNAc,
it is likely that O-GlcNAcylation of other transcription factors
could regulate gene expression in response to glucose use.
HDIs are able to restore the expression of 2% of the total
number of human genes (17), e.g., the cyclin-dependent kinase
inhibitor p21 whose up-regulation is considered to be
responsible for the antiproliferative effect of the drug (17, 34).
A number of studies have shown that p21 expression causes G1
cell cycle arrest and protects cells against chemotherapeutic
agents (18, 35, 36). However, among cells that have HDI-
induced p21 expression, only cells in late G1 and S phase
proceed through an aberrant mitosis and rapid apoptosis,
whereas cells in G1 phase accumulate p21 and undergo cell
cycle arrest. Our results show that LAQ824, TSA, and NaB
applied alone induced a transient increase of p21 protein levels
that is completely abolished upon addition of 2-DG, which
then drives the cells into apoptosis.
Other drug combinations (37), e.g., cisplatin and the
rapamycin derivative RAD001 (38), the HSP90 antagonist 17-
AAG, and NaB (39, 40), can induce similar synergism regarding
the implication of p21 proteins in the regulation of cell
survival. We therefore conclude that the p21 response to some
drug combinations including HDIs is not the causative factor of
induction of tumor cell apoptosis because marked decrease of
p21 levels also accompanied induction of widespread tumor
cell death in the combination of 2-DG with HDI. Nonetheless,
p21 background slightly influences cell death response upon
drug application, as found when exposing p21–wild-type and
p21-knock out cancer cells.
In conclusion, we propose to develop a clinical protocol that
explores the therapeutic potential of a combination of 2-DG
and LAQ824 for glioblastoma that can be extended to other
malignancies such as breast and cervix cancer.
Disclosure of Potential Conflicts of Interest
Novartis covered 25% of all expenses and 75% of noncommercial expenses of
the research.
Acknowledgments
We thank Prof. Bert Vogelstein for the HCT 116 p21+/+ and p21-/- cell lines,
Dr Brian Hemmings for the anti-Akt antibodies, Dr GeorgeThomas for the anti-S6
antibodies, Novartis Pharma AG, Switzerland for providing the LAQ824 compound,
and Dr. KennethTakeda for supervising the thesis work ofViviane Egler.
Cell Apoptosis by HDACand Glycolisis Inhibition
www.aacrjournals.org Clin Cancer Res 2008;14(10) May15, 20083139
References
1.Wechsler-Reya R, Scott MP. The developmental biol-
ogy of brain tumors. Annu Rev Neurosci 2001;24:
385^428.
2. ZhuY, Parada LF. The molecular and genetic basis
of neurological tumours. Nat Rev Cancer 2002;2:
616^26.
3. KondoY, Hollingsworth EF, Kondo S. Molecular tar-
geting for malignant gliomas (Review). Int J Oncol
2004;24:1101^9.
4. Ishii N, Maier D, Merlo A, et al. Frequent co-
alterations of TP53, p16/CDKN2A, p14ARF, PTEN
tumor suppressor genes in human glioma cell lines.
Brain Pathol 1999;9:469^79.
5. Mellinghoff IK, CloughesyTF, Mischel PS. PTEN-
mediated resistance to epidermal growth factor recep-
tor kinase inhibitors.ClinCancerRes2007;13:378^81.
6. Nicholas MK, Lukas RV, Jafri NF, Faoro L, Salgia R.
Epidermal growth factor receptor - mediated signal
transduction in the development and therapy of glio-
mas. Clin Cancer Res 2006;12:7261^70.
7. Hynes NE, Lane HA. ERBB receptors and cancer: the
complexity of targeted inhibitors. Nat Rev Cancer
2005;5:341^54.
8. Evan GI, Vousden KH. Proliferation, cell cycle and
apoptosis in cancer. Nature 2001;411:342^8.
9. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S,
van Kuilenburg AB. Histone deacetylases (HDACs):
characterization of the classical HDAC family. Bio-
chemJ 2003;370:737^49.
10. CressWD, Seto E. Histone deacetylases, transcrip-
tional control, and cancer. J Cell Physiol 2000;184:
1^16.
11. Johnstone RW. Histone-deacetylase inhibitors:
novel drugs for the treatment of cancer. Nat Rev Drug
Discov 2002;1:287^99.
12. MacLachlan TK, Sang N, Giordano A. Cyclins,
cyclin-dependent kinases and cdk inhibitors: implica-
tions in cell cycle control and cancer. Crit RevEukaryot
Gene Expr1995;5:127^56.
13. Atadja P, Gao L, Kwon P, et al. Selective growth
inhibition of tumor cells by a novel histone deacety-
lase inhibitor, NVP-LAQ824. Cancer Res 2004;64:
689^95.
14.Weisberg E, Catley L, KujawaJ, et al. Histone deace-
tylase inhibitor NVP-LAQ824 has significant activity
against myeloid leukemia cells in vitro and in vivo.
Leukemia 2004;18:1951^63.
15. Nimmanapalli R, Fuino L, Bali P, et al. Histone
deacetylase inhibitor LAQ824 both lowers expression
and promotes proteasomal degradation of Bcr-Abl
and induces apoptosis of imatinib mesylate-sensitive
or -refractory chronic myelogenous leukemia-blast
crisis cells. Cancer Res 2003;63:5126^35.
16. Nimmanapalli R, Fuino L, Stobaugh C, Richon V,
Bhalla K. Cotreatment with the histone deacetylase
inhibitor suberoylanilide hydroxamic acid (SAHA)
enhances imatinib-induced apoptosis of Bcr-Abl-
positive human acute leukemia cells. Blood 2003;
101:3236^9.
17. Richon VM, Sandhoff TW, Rifkind RA, Marks PA.
Histone deacetylase inhibitor selectively induces
p21WAF1 expression and gene-associated histone
acetylation. Proc Natl Acad Sci U S A 2000;97:
10014^9.
18. Burgess AJ, Pavey S,Warrener R, et al. Up-regula-
tion of p21(WAF1/CIP1) by histone deacetylase inhib-
itors reduces their cytotoxicity. Mol Pharmacol 2001;
60:828^37.
19. Novak L, Molnar P, Lengyel Z, Tron L. Does in-
creased 18FDG uptake reflect malignant transforma-
tion of a low-grade glioma? A diagnostic dilemma.
Neurol India 2005;53:112^4.
20. Gatenby RA, Gillies RJ.Why do cancers have high
aerobic glycolysis? Nat Rev Cancer 2004;4:891^9.
21. Kaplan O, Navon G, Lyon RC, Faustino PJ, Straka
EJ, Cohen JS. Effects of 2-deoxyglucose on drug-
sensitive and drug-resistant human breast cancer
cells: toxicity and magnetic resonance spectroscopy
studies of metabolism. Cancer Res 1990;50:
544^51.
22.Gallagher BM, FowlerJS, Gutterson NI, MacGregor
RR,WanCN,Wolf AP.Metabolic trapping as a principle
of oradiopharmaceutical design: some factors respo-
sible for the biodistribution of [18F] 2-deoxy-2-
fluoro-D-glucose. JNucl Med1978;19:1154^61.
23. Cay O, Radnell M, Jeppsson B, Ahren B, Bengmark
S. Inhibitory effect of 2-deoxy-D-glucose on liver
tumor growth in rats. Cancer Res1992;52:5794^6.
24. Dwarkanath BS, Zolzer F, Chandana S, et al.
Heterogeneity in 2-deoxy-D-glucose-induced modifi-
cations in energetics and radiation responses of
human tumor cell lines. Int J Radiat Oncol Biol Phys
2001;50:1051^61.
25. Mohanti BK, Rath GK, Anantha N, et al. Improving
cancer radiotherapy with 2-deoxy-D-glucose: phase
I/II clinical trials on human cerebral gliomas. Int J
Radiat Oncol Biol Phys1996;35:103^11.
26. Failly M, Korur S, Egler V, et al. Combination of
sublethal concentrations of epidermal growth factor
receptor inhibitor and microtubule stabilizer induces
apoptosis of glioblastoma cells. Mol Cancer Ther
2007;6:773^81.
27.WaldmanT, Kinzler KW,Vogelstein B. p21 is neces-
sary for the p53-mediated G1arrest in human cancer
cells. Cancer Res1995;55:5187^90.
Cancer Therapy: Preclinical
www.aacrjournals.orgClin Cancer Res 2008;14(10) May15, 2008 3140
28. FischerM, Kaech S, Knutti D,Matus A. Rapid actin-
based plasticity in dendritic spines. Neuron 1998;20:
847^54.
29.Han I, KudlowJE. ReducedOglycosylationof Sp1is
associated with increased proteasome susceptibility.
Mol Cell Biol 1997;17:2550^8.
30. Kang HT, Ju JW, Cho JW, Hwang ES. Down-
regulation of Sp1activity through modulation of O-
glycosylationby treatmentwitha lowglucosemimetic,
2-deoxyglucose. JBiol Chem2003;278:51223^31.
31. Shaw RJ, Bardeesy N, Manning BD, et al.The LKB1
tumor suppressor negatively regulates mTOR signal-
ing. Cancer Cell 2004;6:91^9.
32. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular
energy response to control cell growth and survival.
Cell 2003;115:577^90.
33.Dennis PB, JaeschkeA, SaitohM, Fowler B, Kozma
SC,Thomas G. MammalianTOR: a homeostatic ATP
sensor. Science 2001;294:1102^5.
34. Blagosklonny MV, Robey R, Sackett DL, et al.
Histone deacetylase inhibitors all induce p21 but
differentially cause tubulin acetylation, mitotic
arrest, and cytotoxicity. Mol Cancer Ther 2002;1:
937^41.
35. Fueyo J, Gomez-Manzano C, Puduvalli VK, et al.
Adenovirus-mediated p16 transfer to glioma cells
induces G1 arrest and protects from paclitaxel and
topotecan: implications for therapy. Int J Oncol 1998;
12:665^9.
36. SchmidtM,FanZ.Protectionagainstchemotherapy-
induced cytotoxicity by cyclin-dependent kinase
inhibitors (CKI) in CKI-responsive cells compared
with CKI-unresponsive cells. Oncogene 2001;20:
6164^71.
37. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier
Y, Carrier F. Inhibition of histone deacetylase increases
cytotoxicity to anticancer drugs targeting DNA.
Cancer Res 2003;63:7291^300.
38. Beuvink I, BoulayA, Fumagalli S, et al. The mTOR
inhibitor RAD001 sensitizes tumor cells to DNA-
damaged induced apoptosis through inhibition of p21
translation. Cell 2005;120:747^59.
39. Rahmani M,Yu C, Dai Y, et al. Coadministration of
the heat shock protein 90 antagonist 17-allylamino-
17-demethoxygeldanamycin with suberoylanilide
hydroxamic acid or sodium butyrate synergistically
induces apoptosis in human leukemia cells. Cancer
Res 2003;63:8420^7.
40. Burgess A, Ruefli A, Beamish H, et al. Histone
deacetylase inhibitors specifically kill nonproliferating
tumour cells. Oncogene 2004;23:6693^701.
 78 
 
3. Future Perspectives 
Malignant gliomas remain one of the deadliest of all cancers despite most aggressive 
therapy. Traditional treatments are based on surgical resection and on nonspecific, 
cytotoxic regimens mediating DNA damage. The combat against brain tumors 
experiences particular challenges such as the highly infiltrative, chemo- and radio- 
resistant nature of the cancer cells in addition to the vulnerability of normal brain tissue 
to any intervention (Merlo, 2003). The probability of 2-year survival for a GBM patient is 
not more than 10% (Stupp et al., 2005) and recurrence occurs in 80% of patients within 2 
cm from the margins of the surgical resection reflecting the highly infiltrative behavior of 
glioma cells (Wallner et al., 1989). Advances in our understanding of the molecular 
biology and characterization of the genetic lesions of brain tumors led the opportunity for 
specific targeting of those tumors with novel agents. However, monotherapies against 
GBM did not show promising effects (Sathornsumetee et al., 2007; Wallner et al., 1989). 
No subtype of GBM has been found to depend on a single tumor suppressor or oncogene 
pathway. The frequent alterations in several non-redundant signaling pathways in GBM 
pathogenesis gave those cells their unique malignant characteristics. It seems unlikely 
that therapeutics towards a single target will help to achieve tumor control in GBM 
patients. The clinical evaluation of several single agents showed only modest effects in a 
minority of the GBM patients (Sathornsumetee et al., 2007). In order to efficiently induce 
cell death combinatorial therapies targeting non-overlapping pathways will be a 
prequisite. In addition, cancer cells may compensate for a single specific molecular 
inhibition by activating upstream feedback loops from the primary target and thus, dual 
targeting in a pathway upstream and downstream might be more successful.  
Another attractive strategy would be targeting the same signaling pathway at two 
different levels to maximize the level of inhibition. Novel preclinical studies showed the 
success of that strategy, for example one study showed that combination of inhibitors of 
translation initiation; MNK (CGP57380) and mTOR (Rapamycin) both acting on the 
same pathway but at different levels had an additive effect on growth inhibition in 
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glioblastoma cell lines. MNK inhibitor reduced the light ribosomal fractions (40/60/80S) 
and the latter inhibitor reduced the global ribosome abundance explaining the mode of 
additive effect (Grzmil et al., 2009). In another report two drugs targeting EGFR; 
cetuximab (blocking ligand binding) and gefinitib (inhibitor of tyrosine kinase activity) 
offered combinatorial benefit in head and neck cancers by showing more pronounced 
down regulation of downstream pathways (Huang et al., 2004). Two different 
monoclonal antibodies against ERBB2: trastuzumab and pertuzumab showed synergistic 
effects on breast cancer cells (Nahta et al., 2004) and the reason behind this phenomenon 
was shown that ERBB receptors can utilize two different activation modes for relaying 
downstream signals and combination of those antibodies inhibit both modes by binding to 
different critical domains on ERBB2. Trastuzumab inhibits ligand independent 
dimerization of ERBB2 with ERBB3, whereas pertuzumab inhibits ligand dependent 
ERBB2 dimerization with other growth factor receptors including ERBB3. Thus, 
inhibiting different modes of activation of a single receptor may enhance the success of 
the therapy by limiting compensating mechanisms. On the other hand, it was found that 
ERBB2 overexpressing cells with PI3K mutations were insensitive to trastuzumab 
because PI3K resides downstream of ERBB2 and trastuzumab could not prevent 
activation of PKB (Junttila et al., 2009). Thus, it is required to inhibit PI3K to block 
growth of those kinds of cancer cells. Future work giving a deeper insight into the 
regulatory mechanisms used by receptor tyrosine kinases and downstream effectors, and 
analysis of efficiency of targeted therapies and identification of the mechanisms behind 
the failure and/or resistance will help us to develop more efficient treatments.  
Using combinatorial approaches in our lab, we discovered a specific strong 
synergistic induction of cell death upon targeting energy metabolism together with 
disruption of epigenetic regulation with histone deactylase inhibitors. We speculate that 
re-expression of the silenced genes by HDIs lowered the apoptotic threshold of glioma 
cells which becomes even more pronounced under energy deprivation leading to a 
synergistic induction of cell death. The other synergistic effect we found by combining a 
cytotoxic drug with a targeted drug (AEE788 and patupilone) proves the potential of 
those kinds of combinations as well. A strategy is needed to determine the most 
promising combinations because the possible combinations are unlimited. The successful 
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therapeutic agent for GBM must be highly selective for cancer cells relative to the normal 
cells. In addition, efficient delivery across blood brain barrier into the brain parenchyma 
is required. Furthermore, the synergistic effects shown by combining two drugs might 
allow lowering the doses of the single agents and increase the patient tolerance. 
Growing evidence indicates that many types of tumors are maintained by a rare 
population of stem cell like cancer cells which are thought to be the reason behind the 
chemo- and radio- resistant behavior of the tumor (Bao et al., 2006; Dean et al., 2005; 
Visvader and Lindeman, 2008). Many pathways involved in the control of normal stem 
cells are often found to be deregulated in cancer. Tumor development involves properties 
such as self-renewal and unlimited growth potential. Elucidating regulatory mechanisms 
shared between normal and cancer stem cells might facilitate the identification of novel 
therapeutic targets. To this end, it is necessary to further identify better markers for 
cancer initiating cells. 
Recently, it was shown that cells derived from glioblastoma tumor samples grown 
in the neurobasal medium with bFGF and EGF more closely mirror primary tumors than 
serum cultured cell lines. This fact is represented by the phenotypic and genotypic 
similarities of those cells with the original tumor, unlike the highly discrepant genomic 
profile with the corresponding serum grown cell lines (Lee et al., 2006). Thus, it is 
crucial to expand findings with serum-cultured cells to neurobasal medium-grown ex vivo 
cell lines. Growing evidence challenged the initial judgment about CD133 positive cells 
as the universal cancer stem cell marker in brain tumors. Our finding that the cancer stem 
cells in a primary glioblastoma sample are contained in the CD133-negative population in 
BS287 ex vivo cell line, also contradicted the initial reports. Indeed, CD133-negative 
cells were also found to have stem cell characteristics, which differ, from the CD133+ 
cells. Beier et al proved that the CD133+ CSCs represent only a subset of primary GBM. 
CD133- tumor cells also possess stem cell like characteristics but with distinct genomic 
profiles and growth characteristics (Beier et al., 2007). Interestingly, Wang et al showed 
that CD133- cells are tumorigenic and CD133+ cells can be obtained from the tumors 
formed by the CD133- cells. CD133+ cells start to appear coinciding with angiogenesis 
and shorter survival suggesting that they are not required to initiate the tumor, but are 
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involved during brain tumor progression (Wang et al., 2008a). Griguer et al showed that 
CD133 expression is elevated under hypoxic conditions and with mitochondrial 
dysfunction, suggesting that CD133 is a marker of bio-energetic stress in GBM (Griguer 
et al., 2008). Additionally, the fact that xenotransplantation assays are used in order to 
identify the tumor initiating cells may lead to incorrect conclusions as these assays may 
select for cells that are able to survive in a foreign host but not represent cells with 
superior abilities (Read et al., 2009). Read et al also have shown that in a mouse model of 
medulloblastoma CD133- cells were the cells capable of initiating tumors. For all of the 
above-mentioned reasons the concept that CD133 is a CSC marker needs to be revised. 
Cancer cells usually upregulate several pathways in order to increase their 
apoptotic threshold, and the efficacy of cell death inducing drugs by causing cell damage 
has proven limited efficacy (Hanahan and Weinberg, 2000). Another attractive approach 
for the treatment of GBM is differentiation therapy that is based on the concept that 
neoplastic cells are normal cells that have been arrested in an immature or less 
differentiated state. Differentiation therapy aims to force neoplastic cells to resume their 
maturation process (Pierce, 1983). This approach results in tumor reprogramming and a 
concomitant loss in proliferative capacity and induction of terminal differentiation or cell 
death (Leszczyniecka et al., 2001). Although differentiation therapy does not necessarily 
induce cell death, it restrains cell growth and allows the application of the standard 
therapies under more favorable conditions. The first such agent found to be effective was 
all-trans-retinoic acid (ATRA) which is used in the treatment of acute promyelocytic 
leukemia (APL), causing premyelocytes to mature and stop proliferating (Huang et al., 
1988). An agent that showed promising effects in GBM was BMP4. It has an instructive 
role in the development of normal brain. However, it was also found to induce 
differentiation of brain tumor initiating cells and prolonged survival in the mice 
transplanted with GBM (Piccirillo and Vescovi, 2006). It is well plausible that the future 
work utilizing differentiation inducing therapeutic approaches will aid us to make bigger 
steps in the race for more efficient treatment options. 
Bmi1, is a member of the polycomb group proteins, which are involved in the 
regulation of chromatin structure to fine-tune the expression of specific sets of genes 
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required for a certain developmental stage (Orlando, 2003). One major function of Bmi1 
is to repress Ink4a/Arf locus, which is frequently deleted in brain tumors (Labuhn et al., 
2001). These data commended that high Bmi1 protein levels could influence brain tumor 
development by repressing the Ink4a/Arf locus. Nonetheless, Bmi1 down-regulation did 
not affect the Ink4a/Arf expression in the tumor cell lines analyzed. Hence, in GBM, we 
proposed that Bmi1 is possibly influencing distinct pathways. We have shown that down-
regulation of Bmi1 reduced GSK3! protein, and in turn, induced differentiation in cancer 
cells, and markedly reduced tumor cell proliferation, survival, migration and 
clonogenicity without affecting Ink4a/Arf expression. Clonogenic potential of cancer 
cells is reflected on their self-renewal capacity. One important role of Bmi1 is to regulate 
stem cell self-renewal, which is also a cardinal feature of cancer cells. Thus, our results 
identified a critical function of Bmi1-GSK3 route in GBM cancer cell identity. Inhibition 
of GSK3 induced tumor cell reprogramming with a concomitant loss of stem cell related 
markers and a stronger expression of differentiation markers. This led to a decrease in the 
stem cell like population and a reduction in the colony-forming abilities. The efficacy of 
differentiation therapy has not yet been broadly analyzed in cancers. Our findings show 
that inhibiting pathways controlling normal stem cell self-renewal, also affects growth 
and renewal of cancer cells and might lead to novel therapeutic approaches against GBM. 
Although discovered three decades ago (Hemmings et al., 1981), glycogen 
synthase kinase 3 has only recently been considered as a therapeutic target for cancer 
therapies (Ougolkov et al., 2005; Wang et al., 2008b). GSK3 inhibits Wnt, Hedgehog and 
Notch signaling, which are activated in several cancers (Foltz et al., 2002; Polakis, 2000) 
This suggests a therapeutically negative pro-survival effect of GSK3 inhibitors in cancer 
cells. This, however, may not be true since long-term medical use of the GSK3 inhibitor 
lithium chloride in psychiatric patients did not result in increased cancer incidence 
(Cohen et al., 1998) and also normal cells might well be equipped with preventive 
mechanisms to balance activation of oncogenic pathways by GSK3 inhibitors. Likewise, 
Cohen et al. demonstrated that psychiatric patients on long-term Lithium chloride 
medication have a lower cancer prevalence compared to the general population (Cohen et 
al., 1998), Surprisingly, this would suggest a protective effect of Lithium chloride. Our 
results represent a molecular explanation for this epidemiological observation: 
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administration of Lithium chloride drives differentiation, inhibits proliferation and 
thereby might effectively inhibit tumor formation and progression. Additionally, 
excessive clinical data on Lithium chloride offer solid information on potential side 
effects, and it appears safe to assume that normal adult stem cells are not negatively 
affected even by long-term use of Lithium chloride. The complementary phenotypic and 
functional alterations induced by either inhibiting GSK3 or by down-regulating Bmi1 in 
this study points to a functional link between Bmi1 and GSK3. Nonetheless, further 
studies are needed to clarify the nature of the bond between Bmi1 and GSK3. In essence, 
as inhibitors of Bmi1 activity do not exist, GSK3 down-regulation can be viewed as a 
novel approach to efficiently block the subpopulation of cancer cells that contain a cancer 
stem cell like signature, inducing differentiation. 
Sox2 protein is important for self-renewal of embryonic stem cells and has also 
been implicated to play a role in GBM (Fong et al., 2008; Gangemi et al., 2008). Down-
regulation of Sox2 reduced cell proliferation and tumorigenicity in GBM. Sox2 was 
therefore proposed as a new therapeutic target for GBM (Gangemi et al., 2008). At 
present, inhibitors of Sox2 are not available. Our data show, however, that inhibition of 
GSK3 strongly down-regulates Sox2 in GBM. Thus, by applying Lithium chloride or 
SB216763 we can interfere with Sox2-dependent tumorigenic potential in GBM tumors.  
Two main approaches are currently being investigated to eradicate the cancer 
stem cell (CSC) pool. One method is based on chemotherapeutic regimens, which 
specifically drive CSCs into apoptosis and thereby deplete the CSC reservoir of the 
tumor. The other method, aims to drive CSC into differentiation along with lowering 
their apoptotic threshold, thereby increasing their susceptibility to pro-apoptotic stimuli 
(Visvader and Lindeman, 2008). Two important facts  -high degree of drug resistance and 
the shared cellular and gene expression profile between adult and cancer stem cells (Ben-
Porath et al., 2008)- made specific targeting of CSCs difficult. Induction of 
differentiation represents a therapeutic strategy for CSC as Piccirillo et al. showed that 
bone morphogenetic proteins (BMP) can induce differentiation of CD133-positive GBM 
cells, thereby reducing their tumorigenic potential (Piccirillo and Vescovi, 2006). One 
concern with the use of morphogens is the risk of interfering with the tightly regulated 
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adult stem cell niches. Therefore, a strategy to induce differentiation in cancer stem cells 
has to be carefully assessed for any adverse effect on the adult stem cell population. 
Our findings proposes GSK3 inhibition as an attractive strategy to specifically 
target a subpopulation of cancer cells with stem cell like characteristics. Expression of 
stem cell and differentiation markers define more accurately the subpopulation of cells 
within GBM cell lines and the ex vivo tumor cells than expression of the CD133 marker. 
Inactivation of either Bmi1 or GSK3 depleted precursor cells required for tumor 
maintenance and progression. Our data add another facet to the diverse effects of GSK3 
as a regulator of cancer cell identity. Here, we identified GSK3 activation as a key 
element in maintaining stem cell like characteristics in a subset of cancer cells with 
higher self-renewal capacity. Recent reports corroborated our findings on the importance 
of GSK3 in GBM, as down-regulation of GSK3 was shown to induce apoptosis and to 
have an anti-migratory effect in glioma spheroids (Nowicki et al., 2008; Kotliarova et al., 
2008), however, its effect on cell identity had not been analyzed.  
GSK3 inhibitors consistently lead to accumulation of !-catenin protein, which 
then might drive cell proliferation. However, we did not observe increased proliferation. 
This may be explained by the constitutive activation of several growth promoting 
pathways such as EGFR and PI3K commonly activated in GBM, which could lead to 
saturation of Wnt signaling and masking additional activation. Conversely, pro-
differentiation and pro-apoptotic programs, which have to be kept low in cancer cells, 
could be influenced by shRNAs against Bmi1, downregulating not only GSK3, but also 
Bcl2, Nestin, Sox2. Our microarray and protein data showed increased levels of GSK3! 
expression in brain tumors compared to normal brain tissue indicating a role of GSK3! in 
GBM. Down-regulation of GSK3 depleted the cancer stem cell population. GSK3 can 
therefore be regarded as an important regulator of tumor cell identity in GBM. Therefore, 
we propose GSK3 inhibition (e.g. Lithium chloride) as a complementary approach to 
standard therapy. Following control of the nodular tumor component, second line therapy 
with GSK3 inhibition may prevent tumor recurrence by the residual cancer stem cells that 
readily resist standard therapy. 
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Although analysis of glioma cells in vitro and ex vivo represents a fast and reliable 
model to assess therapeutic agents, future studies using an orthotopic rodent GBM model 
are required. An animal model would confirm the effects of our differentiation therapy 
with GSK3 inhibition and combinatorial approaches with histone deacetylase inhibitors 
and 2-DG. These animal studies will also enable us to better evaluate potential side 
effects. In the combat against GBM, a better identification of the tumor initiating cell 
along with an in depth study of the pathways regulating brain tumor initiating cells, 
would open new windows for development of novel drugs. In addition, recent studies 
showed that cancer stem cells as normal stem cells require a niche, specific extracellular 
signals in order to maintain their growth and renewal potential (Sneddon and Werb, 
2007). Inhibition of niche-specific signals and of mechanisms regulating migration of 
normal stem cells might be applicable to limit invasive behavior of brain tumor cells. 
The cancer stem cell field and our knowledge on cancer biology is expanding 
rapidly which will ultimately enable us to interfere and destroy the devastating potential 
of tumor cells in the near future. 
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